US20090149844A1 - Method And Apparatus For Improved Vascular Related Treatment - Google Patents

Method And Apparatus For Improved Vascular Related Treatment Download PDF

Info

Publication number
US20090149844A1
US20090149844A1 US12/210,427 US21042708A US2009149844A1 US 20090149844 A1 US20090149844 A1 US 20090149844A1 US 21042708 A US21042708 A US 21042708A US 2009149844 A1 US2009149844 A1 US 2009149844A1
Authority
US
United States
Prior art keywords
radiation
band
treatment
source
wavelength
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/210,427
Inventor
Gregory Altshuler
Michael Z. Smirnov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palomar Medical Technologies LLC
Original Assignee
Palomar Medical Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palomar Medical Technologies LLC filed Critical Palomar Medical Technologies LLC
Priority to US12/210,427 priority Critical patent/US20090149844A1/en
Publication of US20090149844A1 publication Critical patent/US20090149844A1/en
Assigned to PALOMAR MEDICAL TECHNOLOGIES, LLC reassignment PALOMAR MEDICAL TECHNOLOGIES, LLC MERGER (SEE DOCUMENT FOR DETAILS). Assignors: PALOMAR MEDICAL TECHNOLOGIES, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A61B18/203Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser applying laser energy to the outside of the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452Skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452Skin
    • A61B2018/00458Deeper parts of the skin, e.g. treatment of vascular disorders or port wine stains
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A61B2018/2065Multiwave; Wavelength mixing, e.g. using four or more wavelengths
    • A61B2018/2075Multiwave; Wavelength mixing, e.g. using four or more wavelengths mixing three wavelengths

Definitions

  • This invention relates to methods and apparatus for improved vascular related treatments, and more particularly to methods and apparatus for treating vascular lesions, for skin rejuvenation and for other dermatological treatments where safety and efficacy are enhanced by using only selected portions of the optical spectrum.
  • Optical radiation is currently used to treat a variety of dermatological conditions, including various vascular lesions (for example spider veins, facial telangiectasia, port wine stains, rosacea and erythema, spider angioma, poikloderma of civatte, pyogenic granuloma, venous lakes, cherry anginoma, leg telangiectasia, varicose veins, and hemangioma), skin rejuvenation by regeneration of collagen in the affected area to improve skin texture, eliminating wrinkles, scars and the like, psoriasis, hair growth control, acne, etc.
  • vascular lesions for example spider veins, facial telangiectasia, port wine stains, rosacea and erythema, spider angioma, poikloderma of civatte, pyogenic granuloma, venous lakes, cherry anginoma, leg telangiectasia, varicose veins
  • wavelength bands at which blood has conventionally been treated are also absorbed fairly strongly by melanin. Since there are melanin concentrations in the epidermis of substantially all individuals, such melanin typically being concentrated at the dermal/epidermal junction (DE junction) and there is significant melanin concentration in the epidermis for dark skinned or tanned individuals, the use of these wavelengths to treat vascular lesions and other dermatological and cosmetic conditions can also result in significant heating of the epidermis, and thus cause potential damage to the epidermis, especially for dark skinned patients.
  • DE junction dermal/epidermal junction
  • Such small vessels would include veins and arteries in the papillary dermis in general, including the plexus, and in particular, small blood vessels in the plexus and spider veins.
  • the need for safer and/or more effective treatment methods and apparatus also exists for deeper and/or larger vessels. Such safer and more effective treatment may facilitate the performance of such treatments in spas, salons, the home and other non-clinical settings.
  • this invention provides methods and apparatus for the safe and more effective treatment of various dermatological, including medical and cosmetic, conditions by the heating of blood vessels.
  • shallow vessels primarily plexus vessels and superficial vessels/veins are heated by applying optical radiation to the vessels from a suitable source which radiation includes substantial radiation in a blue wavelength band of approximately 380-450 nm.
  • the optical radiation may be monochromatic radiation in a wavelength range of approximately 400-450 nm, and more preferably in a range of approximately 410-440 nm.
  • radiation from the source may also include radiation in a green-yellow wavelength band of 510 to 595 nm.
  • the radiation may also be non-monochromatic, broadband radiation which, for this aspect of the invention, is in a blue (B) wavelength band from 380 to 450 nm, a green-yellow (GY) wavelength band from 500 to 610 nm, and near infrared (NIR) wavelength band from 800 to 1120 nm, and possibly up to 2800 nm
  • B blue
  • GY green-yellow
  • NIR near infrared
  • the radiation may also have a double band spectrum including approximately in the blue band and also including in a green-yellow band or green-yellow and near infrared bands or blue and near infrared bands.
  • Broadband radiation may have a triple band spectrum which also includes radiation within a band in the blue, the green-yellow and the near infrared (NIR).
  • the treatment may be enhanced by applying pressure and/or cooling to the patient's skin which, among other things, removes blood from blood vessels above blood vessels for which treatment is desired.
  • a broadband optical radiation source is provided, and mechanisms are provided for filtering radiation from the source to pass only wavelengths from the source providing a safety ratio which is approximately at least one and for applying filtered radiation from the source to the blood vessels involved in the treatment.
  • Wavelengths filtered from the radiation may include wavelengths from approximately 610 to 800 nm and preferably wavelengths from approximately 610 nm to 900 nm. Radiation having wavelengths from approximately 450 to 500 nm should also be filtered. Pressure and/or cooling may also be employed for this aspect of the invention.
  • radiation passed as a result of the filtering may include radiation in a blue wavelength band and a green-yellow wavelength band, radiation in an NIR wavelength band also being included for some embodiments, with radiation between the included wavelength bands being filtered out.
  • the passed wavelength bands include a blue wavelength band and an NIR wavelength band, at least some of the radiation therebetween being filtered, or green-yellow and NIR wavelength bands, with radiation there between being filtered out.
  • the invention may also involve filtering the radiation from a broadband source so as to pass to the blood vessels involved in the treatment only selected wavelengths which are in at least two of the blue, green-yellow and NIR wavelength bands, at least some of the radiation in wavelengths between the passed wavelength bands being filtered out. For some embodiments, radiation from all three of the bands is passed.
  • radiation from a broadband source is filtered to pass to the veins involved in the treatment only selected wavelengths from the source, the wavelengths passed and the duration of applied radiation pulses being selected to provide substantially uniform heating of each vein. More particularly, radiation passed is radiation in a green-yellow wavelength band and radiation in an NIR wavelength band, radiation between the bands being filtered out, and the pulse duration is approximately 0.1 to 100 times the thermal relaxation time of the vein involved in the treatment.
  • FIG. 1 is a diagrammatic view of a section of a patient's skin with an apparatus suitable for practicing the teachings of the invention, in accordance with one aspect thereof, positioned thereon;
  • FIG. 2 is a plot of absorption coefficient against wavelength for the main skin chromophores, namely 1—water, 2—melanin, 3—vein blood, and 4—arteria blood;
  • FIG. 3 is a plot of penetration depth of light into the skin against wavelength for Fitzpatrick's skin types I and V;
  • FIGS. 4 a - 4 d are plots of safety ratio for plexus vessels, superficial veins, intermediate veins, and deep veins respectively using short light pulses;
  • FIGS. 5 a - 5 d are plots of action efficiency for plexus vessels, superficial veins, intermediate veins, and deep veins respectively using short light pulses;
  • FIG. 6 is a plot of the output spectrum of an Xe flashlamp using a cutoff filter at 360 nm and a water filter of thickness 3 mm;
  • FIG. 7 is a representation of the pass bands for the various filters and filter combinations or output spectrum which may be utilized for treatments in accordance with the teachings of this invention.
  • FIGS. 8 a and 8 b are plots of temperature as a function of depth in the tissue for lamp treatment of superficial and intermediate veins respectively.
  • FIG. 1 is a graphic representation of a section of a person's skin 10 which includes a dermal layer 12 covered by an epidermal layer 14 , which layers are separated by a dermal-epidermal (DE) junction or basal layer 16 .
  • the upper portion 18 of the dermis is referred to as the papillary dermis and extends roughly 300 microns into the skin, the upper portion of the papillary dermis, extending roughly 20-50 microns into the dermis, being referred to as the plexus 20 .
  • Plexus 20 (1 ⁇ 3 of epidermis thickness) is rich in very small blood vessels, most of which have diameters in the 5 to 20 micron range, with 10 microns being a typical diameter.
  • Papillary dermis 18 including plexus 20 , also contain the collagen and fibroblasts normally involved in skin restructuring for wrinkle removal, scar removal, treatment of skin indentations and treatment of other skin blemishes.
  • FIG. 1 also shows exemplary apparatus for practicing the teachings of the invention.
  • This apparatus includes a head 30 which is preferably adapted to be in contact with the patients skin during treatment and a control box 32 connected to head 30 by an umbilical 34 .
  • a suitable light source of the type discussed later may be in head 30 or in box 32 , umbilical 34 containing light guides in the latter case to deliver light from the source to the head, and containing electrical lines to operate the source in the former case.
  • Box 32 would also normally include suitable controls for the apparatus and may also contain a cooling mechanism, the cooling medium in this case also passing to head 30 through umbilical 34 .
  • the light source may be any suitable light source and may be in either head 30 or control box 32 , for purposes of illustration, the light source is shown in FIG. 1 as a lamp 36 in head 30 with a reflector 38 surrounding the lamp on three sides to direct light from the lamp to an output component 40 which may be a waveguide, lens, contact plate or other suitable output component.
  • a tube 42 may also be provided surrounding lamp 36 , which tube may perform a variety of functions known in the art.
  • the DE junction is typically at about an 0.05-0.15 mm depth in the skin.
  • FIG. 2 shows the calculated absorption coefficients of water ( ⁇ 1000) (1), melanin (2), venous blood (3), and arterial blood (4) as a function of visible and near infrared wavelengths.
  • ⁇ 1000 the absorption coefficients of water
  • melanin (2) the hematocrit of both the arterial and venous blood
  • arterial blood (4) the value of oxygen saturation varies from 0.7 for venous blood to 0.9 for arterial blood.
  • concentration of melanin is set to be the same as that in the basal layer/epidermis of type V skin.
  • collimated light After entering the skin, collimated light loses its directivity and coherence (if present) and becomes diffuse at a distance of roughly 50 to 1000 micrometers due to multiple scattering on skin heterogeneities.
  • radiance which is defined as the total light energy crossing the surface of a unit sphere for a unit time.
  • the radiant exposure (fluence) is the integral of the radiance over the entire period of time that the light strikes the skin.
  • the resultant heat developed is proportional to the product of the radiance and the absorption coefficient. Backscattering in the skin causes the radiance at a point in the skin to exceed the input light flux to such point by up to several times.
  • FIG. 3 shows the calculated penetration depth against wavelength for type I and V skin. As seen in this figure, penetration into the skin falls significantly for normal skin at wavelengths below 450 nm due to increased blood absorption. However, when an external force or cooling is applied to the upper skin surface to occlude the blood vessels comprising the upper vessel plexus, the penetration of light at wavelengths below 450 nm is significantly increased.
  • a safety ratio S is defined such that
  • ⁇ T v is the maximal temperature rise as a result of the treatment at the vessel being treated and ⁇ T b is the maximal temperature rise as a result of heating at basal layer 16 , such temperature rise being primarily due to melanin absorption. It is desired that this ratio be maximized in order to achieve efficient heating of the blood vessel while minimizing pain for the patient and other undesired side effects.
  • AE action efficiency
  • FIGS. 4 a - d and 5 a - d The calculated S and AE for these vessel types for an infinitesimal pulse width shorter than the thermal relaxation time of the vessels are shown in FIGS. 4 a - d and 5 a - d , respectively.
  • the Roman numerals from II to V on the plots indicate the Fitzpatrick's skin types.
  • the safety ratio can be increased by using precooling, parallel cooling and/or longer pulsewidth.
  • NIR range 0.8-1.12 ⁇ m (800-1120 nm).
  • regions 1-3 are related to the aforementioned absorption bands of hemoglobin.
  • the boarders of the B, G and NIR bands can be adjusted around the numbers shown above depending on the depth of the vessels and the patient's skin type.
  • the NIR band is preferably 0.9-1.12 ⁇ m, and the G range is preferably 0.53-0.61.
  • the NIR band can be extended, perhaps up to 2800 nm, to provide non selective heating of superficial parts of the skin. While this increases the action efficiency of the light and provides better use of energy from a broad band light source, it decreases the safety ratio of treatment This expanded NIR band should therefore be used carefully.
  • the B range (the Soret absorption band) provides clear advantages over the other two bands for plexus vessels only.
  • both the B and GY ranges give almost the same safety; however, the B range is somewhat better in respect to treatment efficiency.
  • the best safety is encountered for the GY range.
  • maximum safety is attained using NIR light, however, the GY range provides better efficiency.
  • the safety ratio has a maximum at approximately 0.42-0.44 ⁇ m (i.e. 420-440 nm), has a minimum at about 0.48 ⁇ m and then increases, having maximums at approximately 0.54 and 0.58 ⁇ m before falling off sharply at about 0.6 ⁇ m.
  • the safety ratio rises again, getting close to 1 or over 1 for most skin types, particularly lighter skin types, at 0.8-1.12 ⁇ m (i.e. 800-1120 nm).
  • the preferred wavelengths of treatment are dictated by the safety ratio, and in particular by selecting a wavelength or wavelength band which optimizes the safety ratio for coherent light and which primarily utilizes wavelengths having a safety ratio greater than 1 for incoherent light.
  • monochromatic light sources with wavelengths within the B range can be used. Fluences needed for these treatments can be 2-6 times lower than with traditional treatment using KTP (532 nm) or dye (577-595 nm) lasers.
  • the fluence for vascular treatments can be in the range 1-10 J/cm 2 for pulses shorter than or comparable with the thermal relaxation time (TRT) of the vessels (25 ⁇ s-25 ms).
  • TRT thermal relaxation time
  • a twofold lower fluence can be used for skin texture or wrinkle improvement by plexus heating: 0.5-5 J/cm 2 .
  • blue light does not penetrate much below the skin surface, it is best for plexus vessels and superficial veins and is of little value for intermediate veins.
  • pressure to the skin over the vein to be treated and cooling of the skin can enhance treatment in general, and blue light treatment in particular, for superficial and intermediate veins.
  • TDT thermal damage time
  • the minimal time needed to heat a vein uniformly to its damage temperature is called the thermal damage time (TDT).
  • TDT is the time require to propagate a front of thermal damage to a certain depth in a vessel wall.
  • Theoretical considerations show that the TDT may be from 1.5 to 100 times larger than the thermal relaxation time of the vessel.
  • the TDT may not exist (the temperature distribution in the vein may be very heterogeneous even in the steady state).
  • pulsewidths significantly (1.5-100 times) longer than the thermal relaxation time of the vessel being used in the treatment can permit more uniform heating to be achieved.
  • this mode of treatment requires higher fluences, in the range of for example 10-200 J/cm 2 to be used.
  • monochromatic light sources can be used for vascular related treatments, including skin rejuvenation, using blue light, these lasers including semiconductor lasers, light emitting diode, GaAs semiconductor laser (790-900 nm) with second harmonic generator, OPO, fiber lasers with non linear converter, dye lasers, solid state lasers, etc.
  • lasers for vascular treatments should emit light in one of three bands:
  • Plexus vessels B and/or GY;
  • Deep vessels GY and/or NIR.
  • Alternative light sources can be various types of lamps with proper filtration. Pulsed lamps with high energy have output spectrums which are close to a black body spectrum with certain color temperature. This color temperature can be adjusted by changing current density through the lamp.
  • FIG. 6 shows the spectrum of lamp radiation approximated by the spectrum of blackbody radiation at a temperature of 6000° K. By changing color temperature from 8000° K to 3000° K, it is possible to shift the maximum of lamp energy from the blue light range (B) to near infrared range (NIR).
  • B blue light range
  • NIR near infrared range
  • infrared light with wavelength longer than 1100-1200 nm provides unselective skin heating and can cause pain and other undesirable side effects.
  • the most dangerous wavelength ranges are around the peaks of water absorption at 1.45 ⁇ m and 1.94 ⁇ m ( FIG.
  • the best way to eliminate these wavelengths is to use a water filter.
  • the light passes through a 3 mm thick water filter prior to entering the skin.
  • the water filter removes all spectral features at wavelengths corresponding to the water absorption bands.
  • absorptive glass filters or other types of filters—e.g., dichroic
  • Filtration of short wave lengths is important for wavelengths shorter than 360 nm and is imperative for wavelengths shorter than 290 nm.
  • Ce-doped quartz can be used as a material for such filtration.
  • Optimal filtration for a therapeutic broad band light sources should meet the following criteria:
  • a broad band lamp spectrum can be filtered to provide one or more of the B, GY, and NIR bands as these bands are defined above. Seven different combinations of these bands are possible: B, GY, NIR, BGY, BNIR, GYNIR, BGYNIR (see FIG. 7 ).
  • the second and third criteria depend on physical properties of the filter(s) used. Obviously, no physical filter can have a step-like transmission spectrum. As a result, some tolerance must be allowed in the boundaries between transmission and rejection regions. For example, for the transmission band 500-610 nm, transmission values at ⁇ 1 ⁇ 2 the maximal transmission can be expected at the boundaries of the interval (i.e., 500 nm and 610 nm). Therefore, the actual transmission spectrum at a level of at least 0.1 the maximum value may span from ⁇ 480 to ⁇ 650 nm. As a rule, the actual output spectrum of the lamp after filtration will be broader than the ideal spectrum. Table 2 shows optimal filtration of a lamp or other broad band light source and optimal color temperature of the lamp/source for treatment of different vascular targets.
  • FIG. 8 shows calculated tissue temperature against depth for lamp treatment of superficial (a) and intermediate (b) veins in type II skin.
  • plots 1, 2, and 3 are the vertical temperature profiles in the epidermis (I), dermis (II), and blood (III) using GY, GYNIR, and full (F) spectrum filters, respectively.
  • F is a pass band filter with short wavelength cutoff at 500 nm and long wavelength cutoff at 1120 nm.
  • the incident light is a plane wave infinite in the transverse direction. A rectangular light pulse of duration 20 ms is assumed. In all cases, the input light flux is chosen to provide a maximum blood temperature of 100° C. Therefore, various complex phenomena appearing in biotissues at temperatures above the boiling temperature of water need not be considered.
  • the pass band of the F filter is obtained from that of the GYNIR filter by including the additional spectral range from 610 to 850 nm.
  • Light from the latter range exhibits weak absorption in the dermis, but penetrates deeply therein.
  • the contribution of this spectral range to the total heat source density in the blood is expected to be rather small due to the weak absorption.
  • light from the same range is strongly absorbed by the epidermal melanin, increasing the risk of epidermal injury. Therefore, the F filter is close to the GYNIR filter in treatment efficiency, but is much worse (1.5 times) than both GY and GYNIR from the point of view of the safety.
  • the simulation results shown in FIG. 8 support the above assumption.
  • approximately, 4, 8, and 12.5 J/cm 2 of light energy are needed to heat the blood to the prescribed temperature using the GY, GNIR, and F filters, respectively.
  • the blood temperature is the same for all the filters because almost all of the blood heating is accomplished by the same portion of the spectrum in all cases, even though the available spectrum is different for the various filters; however, the temperature effect on the epidermis is about 1.5 times larger for the F filter than for the G and GNIR filters.
  • the same conclusions hold for the intermediate vein although the required light fluxes are somewhat smaller, being 3.5, 6.7, and 10.5 J/cm 2 for the G, GNIR, and F filters respectively.
  • the temperature effect on the epidermis is, however, substantially the same for the G and GNIR filters.
  • the GYNIR and F filters provide less risk of purpura than the GY filter, providing a more uniform heating of the vein wall.
  • the distinction in heating uniformity is rather small for the superficial vessels, but becomes appreciable with increasing vessel diameter.
  • the GY and GYNIR filters require less energy and decrease the risk of the epidermal injury compared to the F filter.
  • using the GYNIR filter instead of the GY filter increases treatment efficiency since the GYNIR pass band is wider and, therefore, less light energy is filtered out.
  • All filters that transmit or block a part of the spectrum selectively, and are therefore suitable for obtaining the wavelength bands indicated above, can be based on one of four mechanisms: absorption, interference, birefringence or scattering.
  • fluorescence of one or more components of, for example, an absorption filter can be used advantageously.
  • absorption filters In absorption filters, the unwanted regions of the spectrum are absorbed and their energy (excluding fluorescence conversion) is usually converted into heat.
  • Such filters are based on glass, crystals, solutions, gelatin, or plastic containing substances with selective absorption materials such as transition metal ions (Co +2 , Co +3 , Ni +2 , Ti +3 , Cu +2 , V +3 , V +4 , Mn +2 , Mn +3 , Cr +2 , Cr +3 etc.), organic colorants (luminescent and non-luminescent dyes of different origin), charge transfer systems (for example solutions of CuSO 4 *5H 2 O, NiSO 4 *6H2O, CoSO 4 *6H 2 O or K 2 CrO 4 with ligand ions such as ammonia, water, acetate etc), bandgap materials (CdS 1-x :Se x , CdS, GaP etc.), colloidal metals (Au, Ag, Cu), or the color centers.
  • the best NIR or long-pass filters with wavelengths shorter than approximately 800-900 nm cut are based on thermally processed CdS 1-x Se x -doped glass, glass with colloidal Au or liquid or plastic or gel, porous glass or porous transparent ceramic doped with dye.
  • the best visible band-pass filters for blue Band green GY light are based on a combination of glasses doped with transition metals (Cu +2 , Ti +3 , Fe +2 , Co +2 , Co +3 ) and/or solutions of some metal salts with proper ligands (chelats) in liquid or solid matrix.
  • transition metals Cu +2 , Ti +3 , Fe +2 , Co +2 , Co +3
  • chelats proper ligands
  • Other ways to build blue and green-yellow filters are to use solutions or plastics or quartz microspores, glass or sol gel doped with dyes. Absorptive filters are the best in terms of sharpness of transmission boundaries.
  • Interference filters are formed of a sandwich of materials, for example SiO2, TiO2, which have different refractive indices so that a reflection of a different wavelength is obtained from each layer.
  • the pass-band is of the wavelength(s) which are not reflected by any of the layers.
  • IF provides a relatively sharp cut-off, sharper than that of absorption filters for a given incident angle.
  • One drawback is that the transmission spectrum of IF strongly depends on the incident angle of a beam.
  • a lamp has a very wide (360 deg) angular spectrum. Because of that, the border of the output wavelength spectra after IF is significantly wider than after a good absorption filter. To minimize this effect IF should be located at a place in the apparatus used where angular distribution is narrowest, for example on the surface of lamp envelope or on the surface of the tube surrounded the lamp envelope.
  • filters are based on different approaches, such as acousto-optic tunable filters, liquid crystal filters, and filters based on color-selective absorption by surface plasmon at a metal-dielectric interface.
  • Table 3 provides examples of suitable filter materials for the seven different wavelength band combinations indicated above.
  • FILTER/SUBSTANCE NONORGANIC ORGANIC BLUE B FILTER Co 2+ and/or Cu 2+ ionically doped glass (BG12 1 ) STYRYL 6 4 (solvent, plastic, porous CuSO 4 , CoCl 2 solutions with ionically doped glass glass) GREEN (GY) FILTER Cr 3+ and/or Fe 2+ ionically doped glass (BG8 2 , LB6 3 ) DASPI 4 + DNTTCI 4 (solvent, plastic, NiSO 4 solution with ionically doped glass porous glass) NEAR INFRARED (NIR) CdS 1 ⁇ x :Se x colloidally doped glasses (RG730 1 ) STYRYL 9M 4 (solvent, plastic, porous FILTER glass) Commercial azo dyes BGY FILTER Cu 2+ :Fe 2+ ionically doped glass (BG26 1 , DNTTCI 4 (solvent, plastic, porous glass) BG
  • a filter or combinations of filters can be implemented in different locations along the optical path including, for a lamp as shown in FIG. 1 :
  • a filter can also be built as an angular dispersion element (e.g., prism, grating).
  • the radiation beam at the skin surface has a different spectrum (color) at different locations on the surface.
  • Such a beam is referred to as a rainbow beam.
  • Output spectrum can be adjusted by tuning the aperture of the output beam.
  • blue light generally in the preferred range of this invention from 380-450 nm, could not be used in optical radiation dermatology because melanin was so absorbent at these wavelengths that they were too dangerous.
  • the safety ratio at these wavelengths makes it feasible to use these wavelengths for treating shallow blood vessels since the vessels absorb so much more strongly at these wavelengths than at other wavelengths, the energy of the applied radiation may be two to six times less than that for conventional treatments, thereby minimizing epidermal damage while still achieving the desired temperature rise in the blood vessels.
  • pressure may be utilized to control the depth at which treatment occurs.
  • mild pressure is applied to the treatment area, blood will be forced out of the blood vessels in the plexus area, resulting in greater energy absorption at the deeper spider veins, which would be the treatment target, and improving the safety ratio
  • the pressure is applied to surround the treatment area, blood will be forced into and/or held in the blood vessels in the treatment area, resulting greater energy absorption at the superficial vessels and better treatment of this target.
  • additional pressure may be applied to remove blood from the vessels overlying the vessel on which treatment is desired to enhance the safety ratio for such treatment. Cooling may also be utilized to remove blood from upper vessels, particularly plexus vessels.
  • the teachings of this invention may also be used to treat port wine stain by destroying the blood vessels causing this condition, and psoriasis by destroying the vascularization in the plexus area which supports the psoriasis plaque, as well as rosacea, telagiecasia, and hemangioma by similar mechanisms in the plexus area.
  • tissue in the area of these vessels may be heated, for example to approximately 60-70° C.
  • the perturbing of these blood vessels stimulates fibroblasts to be produced, facilitating the growth of new collagen in this area, and thus the removal of wrinkles, scars and other skin blemishes.
  • Heating of the superficial, intermediate and deep veins may also be utilized to either treat the veins themselves, for example to remove the veins, or to heat surrounding tissue to effect some other desired treatment.
  • blood in the vessels can be used as a chromophore for treatment of problems associated with other organs/body components.
  • Rapidly proliferating cells in organs such as hair follicles, sebaceous follicles or glands, pigmented lesions, epidermis, nails and tumors need adequate blood supply, which is provided by well developed vascular systems. Causing damage to the blood supply system or inducing heat diffusion from vessels to the surrounding tissue can trigger other mechanisms to treat such an organ.
  • Superficial and deep arteriovenuos plexuses can be targeted for treatment of skin texture and wrinkles. Heating of vessels in plexuses can cause an inflammatory reaction of surrounding tissue and stimulate influx of fibroblasts for collagen production. As a result, skin texture, wrinkles, and dermis-hypodermis junction and elasticity of skin can be improved.
  • Cellulite can also be reduced by artefiovenuos plexus treatment.
  • Highly vasculated muscular tissue can be treated using the techniques of the present invention in areas of the body with thin skin, particularly above subcutaneous regions (face, neck).
  • skin lifting and deep wrinkle improvement can be achieved.
  • the present invention in addition to vascular lesion treatment, can be used for hair growth management (reduction and stimulation), acne reduction and prevention, pigmented lesion treatment, skin texture and wrinkles improvement, skin elasticity improvement, cellulite reduction, nail disease treatment, cutaneous tumor treatment, skin lifting, odor production reduction etc.
  • the spot size for treatments employing the teachings of this invention are preferably small, for example in the range between 0.1-1 cm for a laser and 0.1-5 cm for a lamp for vessels at a depth of approximately 1 mm or less, and somewhat larger for deeper vessels. Where blood vessels are being treated, this small spot size can be applied at selected points along the blood vessel to destroy the vessel rather than over the entire vessel, clotting at several points along the vessel normally being sufficient to destroy the vessel.
  • Power and fluence should be sufficient to heat blood in the vessels to a temperature of 50-10° C.

Abstract

Methods and apparatus are provided for selectively heating blood vessels in a patients skin to effect a desired dermatological (medical or cosmetic) treatment. For shallow vessels, particularly plexus vessels and superficial vessels/veins, radiation is applied to the vessels involved in the treatment which includes substantial radiation in a blue band of approximately 380-450 nm. The invention also involves maximizing the radiation used for which the safety radio for the area being treated is greater then one and minimizing the radiation used for which the safety ratio is less then one. This generally involves, depending on the blood vessel involved in the treatment and the patient's skin type, using radiation in one or more of a blue, green-yellow and near infrared wavelength band and filtering out radiation at other wavelengths, including radiation between the wavelength bands used.

Description

    RELATED APPLICATIONS
  • This non-provisional application claims the benefit under Title 35, U.S.C. §119(e) of co-pending U.S. provisional application Ser. No. 60/343,811, filed Dec. 27, 2001, which is incorporated herein by reference.
  • FIELD OF THE INVENTION
  • This invention relates to methods and apparatus for improved vascular related treatments, and more particularly to methods and apparatus for treating vascular lesions, for skin rejuvenation and for other dermatological treatments where safety and efficacy are enhanced by using only selected portions of the optical spectrum.
  • BACKGROUND OF THE INVENTION
  • Optical radiation is currently used to treat a variety of dermatological conditions, including various vascular lesions (for example spider veins, facial telangiectasia, port wine stains, rosacea and erythema, spider angioma, poikloderma of civatte, pyogenic granuloma, venous lakes, cherry anginoma, leg telangiectasia, varicose veins, and hemangioma), skin rejuvenation by regeneration of collagen in the affected area to improve skin texture, eliminating wrinkles, scars and the like, psoriasis, hair growth control, acne, etc. Conventional treatments for vascular lesions have involved the use of lasers operating in a wavelength band from approximately 520 nm to 600 nm for shallow veins, wavelengths at which blood has relatively high absorption and at wavelengths from approximately 750 nm to 1060 nm for deep veins, but have generally not operated at wavelengths below 488 nm. Where broad spectrum lamps are used, the lamps have typically been band-pass filtered to operate in a range of approximately 510 nm to 1,200 nm, depending on a number of factors, including the size of the vessel on which treatment is to be performed. For example, U.S. Pat. Nos. 5,620,478 and 5,755,751 reflect conventional wisdom, suggesting wavelength bands as follows:
  • Arteries less than 0.1 mm in diameter—520 to 650 nm;
    Veins less than 0.1 mm in diameter—520 to 700 nm;
    Vessels between 0.1-1.0 mm in diameter—550 to 1,000 nm; and
    Larger vessels—600 to 1,000 nm.
  • However, most of the wavelength bands at which blood has conventionally been treated are also absorbed fairly strongly by melanin. Since there are melanin concentrations in the epidermis of substantially all individuals, such melanin typically being concentrated at the dermal/epidermal junction (DE junction) and there is significant melanin concentration in the epidermis for dark skinned or tanned individuals, the use of these wavelengths to treat vascular lesions and other dermatological and cosmetic conditions can also result in significant heating of the epidermis, and thus cause potential damage to the epidermis, especially for dark skinned patients. This has limited the optical radiation dosage which can be applied in some applications and has frequently required cooling of the epidermis, sometimes aggressive cooling, which can add significantly to the cost of the apparatus used for the treatment, and can also make the apparatus bulky and more difficult to use. Even with cooling, heating of the epidermis may result in some patient discomfort, and may even prevent treatment from being performed on certain very dark skinned individuals.
  • Similarly, water is present in all cells and intercellular space of the body so that targeting water can also result in the heating of epidermal tissue and other tissue outside of the desired treatment area. Thus, care must again be exercised to assure that the treatment does not result in undesired epidermal or other tissue damage. Because of this, phototreatment of vascular targets can currently be performed only by an experienced physician or other highly trained person in a clinical setting using expensive apparatus.
  • A need therefore exists for improved methods and apparatus, and in particular, safer and/or more effective methods and apparatus, for treating various vascular related conditions including, but not limited to, treating vascular lesions, performing skin regeneration, and treating other skin conditions associated with organs or other body elements having blood supply systems, particularly ones involving treatment of small blood vessels relatively close to the skin surface, for example within approximately 0.5 mm of the skin surface. Such small vessels would include veins and arteries in the papillary dermis in general, including the plexus, and in particular, small blood vessels in the plexus and spider veins. However, the need for safer and/or more effective treatment methods and apparatus also exists for deeper and/or larger vessels. Such safer and more effective treatment may facilitate the performance of such treatments in spas, salons, the home and other non-clinical settings.
  • SUMMARY OF THE INVENTION
  • In accordance with the above, this invention provides methods and apparatus for the safe and more effective treatment of various dermatological, including medical and cosmetic, conditions by the heating of blood vessels.
  • In accordance with one aspect of the invention, shallow vessels, primarily plexus vessels and superficial vessels/veins are heated by applying optical radiation to the vessels from a suitable source which radiation includes substantial radiation in a blue wavelength band of approximately 380-450 nm. The optical radiation may be monochromatic radiation in a wavelength range of approximately 400-450 nm, and more preferably in a range of approximately 410-440 nm. For superficial vessels, radiation from the source may also include radiation in a green-yellow wavelength band of 510 to 595 nm. The radiation may also be non-monochromatic, broadband radiation which, for this aspect of the invention, is in a blue (B) wavelength band from 380 to 450 nm, a green-yellow (GY) wavelength band from 500 to 610 nm, and near infrared (NIR) wavelength band from 800 to 1120 nm, and possibly up to 2800 nm The radiation may also have a double band spectrum including approximately in the blue band and also including in a green-yellow band or green-yellow and near infrared bands or blue and near infrared bands. Broadband radiation may have a triple band spectrum which also includes radiation within a band in the blue, the green-yellow and the near infrared (NIR). For the plexus and the superficial vessels one may choose between the blue and the green bands. Alternatively, a double-band spectrum may be of use incorporating both the blue and green-yellow bands or a triple band spectrum can be used. The treatment may be enhanced by applying pressure and/or cooling to the patient's skin which, among other things, removes blood from blood vessels above blood vessels for which treatment is desired.
  • In accordance with another aspect of the invention, a broadband optical radiation source is provided, and mechanisms are provided for filtering radiation from the source to pass only wavelengths from the source providing a safety ratio which is approximately at least one and for applying filtered radiation from the source to the blood vessels involved in the treatment. Wavelengths filtered from the radiation may include wavelengths from approximately 610 to 800 nm and preferably wavelengths from approximately 610 nm to 900 nm. Radiation having wavelengths from approximately 450 to 500 nm should also be filtered. Pressure and/or cooling may also be employed for this aspect of the invention. Stated another way, radiation passed as a result of the filtering may include radiation in a blue wavelength band and a green-yellow wavelength band, radiation in an NIR wavelength band also being included for some embodiments, with radiation between the included wavelength bands being filtered out. Other alternatives are that the passed wavelength bands include a blue wavelength band and an NIR wavelength band, at least some of the radiation therebetween being filtered, or green-yellow and NIR wavelength bands, with radiation there between being filtered out.
  • The invention may also involve filtering the radiation from a broadband source so as to pass to the blood vessels involved in the treatment only selected wavelengths which are in at least two of the blue, green-yellow and NIR wavelength bands, at least some of the radiation in wavelengths between the passed wavelength bands being filtered out. For some embodiments, radiation from all three of the bands is passed.
  • For another aspect of the invention, radiation from a broadband source is filtered to pass to the veins involved in the treatment only selected wavelengths from the source, the wavelengths passed and the duration of applied radiation pulses being selected to provide substantially uniform heating of each vein. More particularly, radiation passed is radiation in a green-yellow wavelength band and radiation in an NIR wavelength band, radiation between the bands being filtered out, and the pulse duration is approximately 0.1 to 100 times the thermal relaxation time of the vein involved in the treatment.
  • The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention as illustrated by the accompanying drawings.
  • IN THE DRAWINGS
  • FIG. 1 is a diagrammatic view of a section of a patient's skin with an apparatus suitable for practicing the teachings of the invention, in accordance with one aspect thereof, positioned thereon;
  • FIG. 2. is a plot of absorption coefficient against wavelength for the main skin chromophores, namely 1—water, 2—melanin, 3—vein blood, and 4—arteria blood;
  • FIG. 3. is a plot of penetration depth of light into the skin against wavelength for Fitzpatrick's skin types I and V;
  • FIGS. 4 a-4 d are plots of safety ratio for plexus vessels, superficial veins, intermediate veins, and deep veins respectively using short light pulses;
  • FIGS. 5 a-5 d are plots of action efficiency for plexus vessels, superficial veins, intermediate veins, and deep veins respectively using short light pulses;
  • FIG. 6 is a plot of the output spectrum of an Xe flashlamp using a cutoff filter at 360 nm and a water filter of thickness 3 mm;
  • FIG. 7 is a representation of the pass bands for the various filters and filter combinations or output spectrum which may be utilized for treatments in accordance with the teachings of this invention; and
  • FIGS. 8 a and 8 b are plots of temperature as a function of depth in the tissue for lamp treatment of superficial and intermediate veins respectively.
  • DETAILED DESCRIPTION
  • FIG. 1 is a graphic representation of a section of a person's skin 10 which includes a dermal layer 12 covered by an epidermal layer 14, which layers are separated by a dermal-epidermal (DE) junction or basal layer 16. The upper portion 18 of the dermis is referred to as the papillary dermis and extends roughly 300 microns into the skin, the upper portion of the papillary dermis, extending roughly 20-50 microns into the dermis, being referred to as the plexus 20. Plexus 20 (⅓ of epidermis thickness) is rich in very small blood vessels, most of which have diameters in the 5 to 20 micron range, with 10 microns being a typical diameter. These plexus vessels are typically at a depth of about 0.05-0.15 mm. Papillary dermis 18, including plexus 20, also contain the collagen and fibroblasts normally involved in skin restructuring for wrinkle removal, scar removal, treatment of skin indentations and treatment of other skin blemishes.
  • In addition to plexus vessels, the teachings of this invention may also be used in treatments involving the following vessels/veins:
      • Superficial veins 22, for example facial spider veins (typical depth 0.25-0.5 mm, typical diameter 0.05-0.3 mm);
      • Intermediate veins 24 (typical depth 0.5-1 mm, typical diameter 0.2-1 mm); and
      • Deep veins 26, for example leg veins, (typical depth 1-5 mm, typical diameter 1-several mm).
  • FIG. 1 also shows exemplary apparatus for practicing the teachings of the invention. This apparatus includes a head 30 which is preferably adapted to be in contact with the patients skin during treatment and a control box 32 connected to head 30 by an umbilical 34. A suitable light source of the type discussed later may be in head 30 or in box 32, umbilical 34 containing light guides in the latter case to deliver light from the source to the head, and containing electrical lines to operate the source in the former case. Box 32 would also normally include suitable controls for the apparatus and may also contain a cooling mechanism, the cooling medium in this case also passing to head 30 through umbilical 34.
  • While as indicated above, the light source may be any suitable light source and may be in either head 30 or control box 32, for purposes of illustration, the light source is shown in FIG. 1 as a lamp 36 in head 30 with a reflector 38 surrounding the lamp on three sides to direct light from the lamp to an output component 40 which may be a waveguide, lens, contact plate or other suitable output component. A tube 42 may also be provided surrounding lamp 36, which tube may perform a variety of functions known in the art.
  • Epidermis 14 in general, and DE junction 16 in particular, contain substantial quantities of melanin, the quantity of melanin at the DE junction increasing as the darkness of the patient's skin increases, being least for light, type I, skin and greatest for very dark, type VI, skin. As the skin becomes darker, there is also increasing amounts of melanin throughout the epidermis, although the largest concentration still remains at the DE junction. The DE junction is typically at about an 0.05-0.15 mm depth in the skin.
  • When dealing with the optical treatment of skin lesions, the absorption spectra of skin constituents are of primary interest. FIG. 2 shows the calculated absorption coefficients of water (×1000) (1), melanin (2), venous blood (3), and arterial blood (4) as a function of visible and near infrared wavelengths. For the calculations of FIG. 2, the hematocrit of both the arterial and venous blood is 0.4 and the value of oxygen saturation varies from 0.7 for venous blood to 0.9 for arterial blood. The concentration of melanin (eumelanin) is set to be the same as that in the basal layer/epidermis of type V skin.
  • After entering the skin, collimated light loses its directivity and coherence (if present) and becomes diffuse at a distance of roughly 50 to 1000 micrometers due to multiple scattering on skin heterogeneities. To describe the thermal effect of the diffuse light, one typically uses a physical quantity known as radiance which is defined as the total light energy crossing the surface of a unit sphere for a unit time. The radiant exposure (fluence) is the integral of the radiance over the entire period of time that the light strikes the skin. When the diffuse light undergoes absorption, the resultant heat developed is proportional to the product of the radiance and the absorption coefficient. Backscattering in the skin causes the radiance at a point in the skin to exceed the input light flux to such point by up to several times. However, as depth in the skin increases, irradiance falls due to both scattering and absorption. The penetration depth of light into the skin may be defined for the following discussion as the depth at which the radiance becomes equal to the input flux. Using this definition, FIG. 3 shows the calculated penetration depth against wavelength for type I and V skin. As seen in this figure, penetration into the skin falls significantly for normal skin at wavelengths below 450 nm due to increased blood absorption. However, when an external force or cooling is applied to the upper skin surface to occlude the blood vessels comprising the upper vessel plexus, the penetration of light at wavelengths below 450 nm is significantly increased.
  • For purposes of this invention, a safety ratio S is defined such that

  • S=ΔT v /ΔT b
  • where ΔTv is the maximal temperature rise as a result of the treatment at the vessel being treated and ΔTb is the maximal temperature rise as a result of heating at basal layer 16, such temperature rise being primarily due to melanin absorption. It is desired that this ratio be maximized in order to achieve efficient heating of the blood vessel while minimizing pain for the patient and other undesired side effects.
  • Another criterion of interest for the purpose of this invention is action efficiency (AE), which is the maximal temperature rise at the target (i.e. the blood vessel) per 1 J/cm2 of the input light flux. The higher the AE value, the less energy is required from the radiation source and therefore, the lower both the device and treatment costs.
  • The specific results of computer simulations will now be considered for the following vessel types which differ in their diameter D and depth H:
  • a. Plexus vessels (D=0.01 mm; H=0.1 mm). FIGS. 4 a, 5 a;
  • b. Superficial vessels (D=0.2 mm; H=0.25 mm). FIGS. 4 b, 5 b;
  • c. Intermediate vessels (D=H=0.5 mm). FIGS. 4 c, 5 c;
  • d. Deep vessels (D=H=1 mm). FIGS. 4 d, 5 d.
  • The calculated S and AE for these vessel types for an infinitesimal pulse width shorter than the thermal relaxation time of the vessels are shown in FIGS. 4 a-d and 5 a-d, respectively. The Roman numerals from II to V on the plots indicate the Fitzpatrick's skin types. The safety ratio can be increased by using precooling, parallel cooling and/or longer pulsewidth.
  • It appears from the simulation data that the spectral regions most promising from the point of view of effective and safe vein/vessel treatment include:
  • 1. Blue range (B) 0.38-0.45 μm (380-450 nm);
  • 2. Green-yellow range (GY) 0.5-0.61 μm (500-610 nm);
  • 3. Near IR range (NIR) 0.8-1.12 μm (800-1120 nm).
  • Apparently, regions 1-3 are related to the aforementioned absorption bands of hemoglobin. The boarders of the B, G and NIR bands can be adjusted around the numbers shown above depending on the depth of the vessels and the patient's skin type. For example, for dark skin, the NIR band is preferably 0.9-1.12 μm, and the G range is preferably 0.53-0.61. For treatment of the plexus and/or superficial vessels, the NIR band can be extended, perhaps up to 2800 nm, to provide non selective heating of superficial parts of the skin. While this increases the action efficiency of the light and provides better use of energy from a broad band light source, it decreases the safety ratio of treatment This expanded NIR band should therefore be used carefully.
  • It should be understood that in any practical implementation of the invention, ideal filtration of a broad-band light source cannot be achieved. As a result, a certain percentage of light energy will be present at wavelengths outside the above-specified bands. Further, light energy may not be distributed absolutely uniformly within the bands due to natural limitations of the light sources and filtration techniques. These circumstances should not be considered as limiting the scope of the present invention.
  • Based on FIGS. 4 and 5, the B range (the Soret absorption band) provides clear advantages over the other two bands for plexus vessels only. For superficial veins, both the B and GY ranges give almost the same safety; however, the B range is somewhat better in respect to treatment efficiency. In the case of intermediate veins, the best safety is encountered for the GY range. Finally, for deep veins, maximum safety is attained using NIR light, however, the GY range provides better efficiency.
  • With these criteria in mind, it can be seen that the safety ratio has a maximum at approximately 0.42-0.44 μm (i.e. 420-440 nm), has a minimum at about 0.48 μm and then increases, having maximums at approximately 0.54 and 0.58 μm before falling off sharply at about 0.6 μm. The safety ratio rises again, getting close to 1 or over 1 for most skin types, particularly lighter skin types, at 0.8-1.12 μm (i.e. 800-1120 nm). The preferred wavelengths of treatment are dictated by the safety ratio, and in particular by selecting a wavelength or wavelength band which optimizes the safety ratio for coherent light and which primarily utilizes wavelengths having a safety ratio greater than 1 for incoherent light.
  • Therefore, for safe and effective treatment of vascular targets at depths up to 0.3 mm, monochromatic light sources with wavelengths within the B range can be used. Fluences needed for these treatments can be 2-6 times lower than with traditional treatment using KTP (532 nm) or dye (577-595 nm) lasers. The fluence for vascular treatments can be in the range 1-10 J/cm2 for pulses shorter than or comparable with the thermal relaxation time (TRT) of the vessels (25 μs-25 ms). A twofold lower fluence can be used for skin texture or wrinkle improvement by plexus heating: 0.5-5 J/cm2. However, because blue light does not penetrate much below the skin surface, it is best for plexus vessels and superficial veins and is of little value for intermediate veins. As discussed later, pressure to the skin over the vein to be treated and cooling of the skin can enhance treatment in general, and blue light treatment in particular, for superficial and intermediate veins.
  • There are some additional issues with the use of blue light in treating blood vessels. Optimum vessel closure can be achieved by denaturization of the endothelium that is in direct contact with blood. The penetration depth of blue light into blood is rather small, being at most 5-30 micrometers. As a result, the vessels undergo inhomogeneous heating. Therefore, the upper and lateral parts of the vein endothelium may be damaged with its lower part remaining intact. This may reduce the efficacy of vein treatment and can be cause of purpura. To solve this problem of inhomogeneous heating, two alternative approaches may be used:
      • 1. The lasing wavelength may be offset from the absorption peaks of hemoglobin;
      • 2. The pulsewidth may be extended.
  • From the above, it seems that choosing the appropriate regions of the spectrum and/or long pulswidths provide rather uniform vein heating. The minimal time needed to heat a vein uniformly to its damage temperature is called the thermal damage time (TDT). TDT is the time require to propagate a front of thermal damage to a certain depth in a vessel wall. Theoretical considerations show that the TDT may be from 1.5 to 100 times larger than the thermal relaxation time of the vessel. However, in some cases, the TDT may not exist (the temperature distribution in the vein may be very heterogeneous even in the steady state). Thus, using pulsewidths significantly (1.5-100 times) longer than the thermal relaxation time of the vessel being used in the treatment can permit more uniform heating to be achieved. However, this mode of treatment requires higher fluences, in the range of for example 10-200 J/cm2 to be used.
  • Various types of monochromatic light sources can be used for vascular related treatments, including skin rejuvenation, using blue light, these lasers including semiconductor lasers, light emitting diode, GaAs semiconductor laser (790-900 nm) with second harmonic generator, OPO, fiber lasers with non linear converter, dye lasers, solid state lasers, etc.
  • According to FIGS. 4 and 5, lasers for vascular treatments should emit light in one of three bands:
  • Plexus vessels: B and/or GY;
  • Superficial vessels: GY and/or B and/or NIR;
  • Intermediate vessels: GY and/or NIR;
  • Deep vessels: GY and/or NIR.
  • More precise ranges of monochromatic (laser) wavelengths for vascular treatment are shown in Table 1.
  • TABLE 1
    Optimal laser wavelengths for vascular treatment
    Skin Skin Skin Skin Skin Skin
    Vessel type I type II type III type IV type V type VI
    Depth, Diameter, Spectra, Spectra, Spectra, Spectra, Spectra, Spectra,
    Type mm mm nm nm nm nm nm nm
    Plexus 0.1 0.01 400-430 405-435 405-435 410-440 410-440 410-440
    Superficial 0.25 0.25 410-440 415-445 415-445 415-445 420-450 420-450
    510-595 510-595 510-595 510-595 540-595 540-595
    Intermediate 0.5 0.5 510-600 510-600 530-600 530-600 530-600 530-600
    Deep >1 >1 510-600 510-600 530-600 530-600 900-1100  900-1100
     800-1100  800-1100  800-1100  850-1100

    Pulsed lasers in these bands, except for the band of 900-1000 nm, have in general very low efficiency (0.1-5%) and high cost.
  • Alternative light sources can be various types of lamps with proper filtration. Pulsed lamps with high energy have output spectrums which are close to a black body spectrum with certain color temperature. This color temperature can be adjusted by changing current density through the lamp. FIG. 6 shows the spectrum of lamp radiation approximated by the spectrum of blackbody radiation at a temperature of 6000° K. By changing color temperature from 8000° K to 3000° K, it is possible to shift the maximum of lamp energy from the blue light range (B) to near infrared range (NIR). For vascular treatment, infrared light with wavelength longer than 1100-1200 nm provides unselective skin heating and can cause pain and other undesirable side effects. The most dangerous wavelength ranges are around the peaks of water absorption at 1.45 μm and 1.94 μm (FIG. 2). The best way to eliminate these wavelengths is to use a water filter. In an example demonstrated by FIG. 6, the light passes through a 3 mm thick water filter prior to entering the skin. The water filter removes all spectral features at wavelengths corresponding to the water absorption bands. In order to eliminate potentially hazardous UV radiation from the output spectrum, absorptive glass filters (or other types of filters—e.g., dichroic) can be used. Filtration of short wave lengths is important for wavelengths shorter than 360 nm and is imperative for wavelengths shorter than 290 nm. Ce-doped quartz can be used as a material for such filtration.
  • For optimal treatment of vascular targets, the present invention suggests a new type of additional filtration, this additional filtration following from the fundamental curves in FIGS. 4-5. Optimal filtration for a therapeutic broad band light sources should meet the following criteria:
  • 1. Maximal transmission of wavelengths with a safety ratio S>1;
  • 2. Maximum attenuation of unwanted wavelengths with safety ratio S<1;
  • 3. Maximally steep boundaries between the two regions.
  • In accordance with the first criterion for safe, effective vascular treatment, a broad band lamp spectrum can be filtered to provide one or more of the B, GY, and NIR bands as these bands are defined above. Seven different combinations of these bands are possible: B, GY, NIR, BGY, BNIR, GYNIR, BGYNIR (see FIG. 7).
  • The second and third criteria depend on physical properties of the filter(s) used. Obviously, no physical filter can have a step-like transmission spectrum. As a result, some tolerance must be allowed in the boundaries between transmission and rejection regions. For example, for the transmission band 500-610 nm, transmission values at ˜½ the maximal transmission can be expected at the boundaries of the interval (i.e., 500 nm and 610 nm). Therefore, the actual transmission spectrum at a level of at least 0.1 the maximum value may span from ˜480 to ˜650 nm. As a rule, the actual output spectrum of the lamp after filtration will be broader than the ideal spectrum. Table 2 shows optimal filtration of a lamp or other broad band light source and optimal color temperature of the lamp/source for treatment of different vascular targets.
  • TABLE 2
    Optimal lamp spectra for vascular treatment
    Vessel Skin type I Skin type II Skin type III
    Type Depth, mm Diameter, mm Tc, ° K Spectra Tc, ° K Spectra Tc, ° K Spectra
    Plexus 0.1 0.01 6000-8000 B 6000-8000 B 6000-8000 B
    BGY BGY BGY
    Superficial 0.25 0.25 5000-7000 B 5000-7000 B 5000-7000 B
    BGY BGY BGY
    BGYNIR BGYNIR BGYNIR
    Intermediate 0.5 0.5 4000-6000 GY 4000-6000 GY 4000-6000 GY
    GYNIR GYNIR GNIR
    Deep
    1 >1 3000-6000 GYNIR 3000-6000 GYNIR 3000-6000 GYNIR
    NIR NIR NIR
    Vessel Skin type IV Skin type V Skin type VI
    Type Depth, mm Diameter, mm Tc, ° K Spectra Tc, ° K Spectra Tc, ° K Spectra
    Plexus 0.1 0.01 6000-8000 B 6000-8000 B 6000-8000 B
    BGY BGY BGY
    Superficial 0.25 0.25 5000-6000 B 4000-6000 B 4000-6000 B
    BGY GY GY
    BGYNIR GYNIR GYNIR
    Intermediate 0.5 0.5 4000-6000 GY 4000-6000 GYNIR 4000-6000 GYNIR
    GYNIR NIR NIR
    Deep
    1 >1 3000-5500 NIR 3000-5500 NIR 3000-4500 NIR
    GYNIR GYNIR
  • The importance of the concepts of the present invention on temperature is illustrated in FIG. 8 where the effect on the skin for a lamp with different filtration is shown. More specifically, FIG. 8 shows calculated tissue temperature against depth for lamp treatment of superficial (a) and intermediate (b) veins in type II skin. Specifically, plots 1, 2, and 3 are the vertical temperature profiles in the epidermis (I), dermis (II), and blood (III) using GY, GYNIR, and full (F) spectrum filters, respectively. Here, F is a pass band filter with short wavelength cutoff at 500 nm and long wavelength cutoff at 1120 nm. The incident light is a plane wave infinite in the transverse direction. A rectangular light pulse of duration 20 ms is assumed. In all cases, the input light flux is chosen to provide a maximum blood temperature of 100° C. Therefore, various complex phenomena appearing in biotissues at temperatures above the boiling temperature of water need not be considered.
  • The pass band of the F filter is obtained from that of the GYNIR filter by including the additional spectral range from 610 to 850 nm. Light from the latter range exhibits weak absorption in the dermis, but penetrates deeply therein. However, the contribution of this spectral range to the total heat source density in the blood is expected to be rather small due to the weak absorption. Contrary to this, light from the same range is strongly absorbed by the epidermal melanin, increasing the risk of epidermal injury. Therefore, the F filter is close to the GYNIR filter in treatment efficiency, but is much worse (1.5 times) than both GY and GYNIR from the point of view of the safety.
  • The simulation results shown in FIG. 8 support the above assumption. For the superficial vein (a), approximately, 4, 8, and 12.5 J/cm2 of light energy are needed to heat the blood to the prescribed temperature using the GY, GNIR, and F filters, respectively. The blood temperature is the same for all the filters because almost all of the blood heating is accomplished by the same portion of the spectrum in all cases, even though the available spectrum is different for the various filters; however, the temperature effect on the epidermis is about 1.5 times larger for the F filter than for the G and GNIR filters. The same conclusions hold for the intermediate vein, although the required light fluxes are somewhat smaller, being 3.5, 6.7, and 10.5 J/cm2 for the G, GNIR, and F filters respectively. The temperature effect on the epidermis is, however, substantially the same for the G and GNIR filters.
  • To choose the best filter for a particular treatment, one needs to take into account that irreversible vein occlusion proceeds through the thermal coagulation of the whole vessel endothelium, including its bottommost part. However, overheating of the topmost part of the vessel wall may disrupt the vessel, leading to purpura. The GYNIR and F filters provide less risk of purpura than the GY filter, providing a more uniform heating of the vein wall. The distinction in heating uniformity is rather small for the superficial vessels, but becomes appreciable with increasing vessel diameter. However, as already mentioned, the GY and GYNIR filters require less energy and decrease the risk of the epidermal injury compared to the F filter. Finally, using the GYNIR filter instead of the GY filter increases treatment efficiency since the GYNIR pass band is wider and, therefore, less light energy is filtered out.
  • All filters that transmit or block a part of the spectrum selectively, and are therefore suitable for obtaining the wavelength bands indicated above, can be based on one of four mechanisms: absorption, interference, birefringence or scattering. In addition, fluorescence of one or more components of, for example, an absorption filter can be used advantageously.
  • In absorption filters, the unwanted regions of the spectrum are absorbed and their energy (excluding fluorescence conversion) is usually converted into heat. Such filters are based on glass, crystals, solutions, gelatin, or plastic containing substances with selective absorption materials such as transition metal ions (Co+2, Co+3, Ni+2, Ti+3, Cu+2, V+3, V+4, Mn+2, Mn+3, Cr+2, Cr+3 etc.), organic colorants (luminescent and non-luminescent dyes of different origin), charge transfer systems (for example solutions of CuSO4*5H2O, NiSO4*6H2O, CoSO4*6H2O or K2CrO4 with ligand ions such as ammonia, water, acetate etc), bandgap materials (CdS1-x:Sex, CdS, GaP etc.), colloidal metals (Au, Ag, Cu), or the color centers.
  • The best NIR or long-pass filters with wavelengths shorter than approximately 800-900 nm cut are based on thermally processed CdS1-xSex-doped glass, glass with colloidal Au or liquid or plastic or gel, porous glass or porous transparent ceramic doped with dye.
  • The best visible band-pass filters for blue Band green GY light are based on a combination of glasses doped with transition metals (Cu+2, Ti+3, Fe+2, Co+2, Co+3) and/or solutions of some metal salts with proper ligands (chelats) in liquid or solid matrix. Other ways to build blue and green-yellow filters are to use solutions or plastics or quartz microspores, glass or sol gel doped with dyes. Absorptive filters are the best in terms of sharpness of transmission boundaries.
  • In scattering filters (Christiansen filters), glass (crystal) powder is suspended in a two-phase compound (liquid/solid, liquid crystal/solid state) with matching refractive index at a certain wavelength and different wavelength dispersion of the refractive index for the two phases. A cuvette filled with such a substance is transparent at a chosen wavelength and scatters at other wavelengths because of refractive index mismatch. Since most liquids or liquid crystals have a stronger variation of refractive index with temperature than do solids, varying the temperature of the composition can be used for spectral tuning of the transmission curve.
  • Interference filters (IF) are formed of a sandwich of materials, for example SiO2, TiO2, which have different refractive indices so that a reflection of a different wavelength is obtained from each layer. The pass-band is of the wavelength(s) which are not reflected by any of the layers. IF provides a relatively sharp cut-off, sharper than that of absorption filters for a given incident angle. One drawback is that the transmission spectrum of IF strongly depends on the incident angle of a beam. A lamp has a very wide (360 deg) angular spectrum. Because of that, the border of the output wavelength spectra after IF is significantly wider than after a good absorption filter. To minimize this effect IF should be located at a place in the apparatus used where angular distribution is narrowest, for example on the surface of lamp envelope or on the surface of the tube surrounded the lamp envelope.
  • Other groups of filters are based on different approaches, such as acousto-optic tunable filters, liquid crystal filters, and filters based on color-selective absorption by surface plasmon at a metal-dielectric interface.
  • Table 3 provides examples of suitable filter materials for the seven different wavelength band combinations indicated above.
  • FILTER/SUBSTANCE NONORGANIC ORGANIC
    BLUE (B) FILTER Co2+ and/or Cu2+ ionically doped glass (BG121) STYRYL 64 (solvent, plastic, porous
    CuSO4, CoCl2 solutions with ionically doped glass glass)
    GREEN (GY) FILTER Cr3+ and/or Fe2+ ionically doped glass (BG82, LB63) DASPI4 + DNTTCI4 (solvent, plastic,
    NiSO4 solution with ionically doped glass porous glass)
    NEAR INFRARED (NIR) CdS1−x:Sex colloidally doped glasses (RG7301) STYRYL 9M4 (solvent, plastic, porous
    FILTER glass)
    Commercial azo dyes
    BGY FILTER Cu2+:Fe2+ ionically doped glass (BG261, DNTTCI4 (solvent, plastic, porous glass)
    BG401 + GG3751)
    CuSO4 solution
    BNIR FILTER Ni2+:Co2+ doped glass (BG31, BGG202, QB193) DASBTI4 (solvent, plastic, porous glass)
    GYNIR FILTER Transient metals ionically doped glass DASPI4 (solvent, plastic, porous glass)
    (LB163 + CB5353)
    BGYNIR FILTER Transient metals ionically doped glass (LB163) Combination of the dyes
  • A filter or combinations of filters can be implemented in different locations along the optical path including, for a lamp as shown in FIG. 1:
      • 1. Coating or material of reflector 38;
      • 2. Material or coating of lamp's envelope;
      • 3. Cooling liquid of the lamp which may be doped by absorption and/or fluorescence particles;
      • 4. Tube 42 surrounding the lamp doped or coated by filtering material;
      • 5. Material or coating on a waveguide or other output component 40;
      • 6. Lotion applied to the patient's skin with the function of reflecting, scattering or absorpting unwanted radiation wavelengths.
  • A filter can also be built as an angular dispersion element (e.g., prism, grating). In this case, the radiation beam at the skin surface has a different spectrum (color) at different locations on the surface. Such a beam is referred to as a rainbow beam. Output spectrum can be adjusted by tuning the aperture of the output beam.
  • In the past it was believed that blue light, generally in the preferred range of this invention from 380-450 nm, could not be used in optical radiation dermatology because melanin was so absorbent at these wavelengths that they were too dangerous. However, as illustrated above, the safety ratio at these wavelengths makes it feasible to use these wavelengths for treating shallow blood vessels since the vessels absorb so much more strongly at these wavelengths than at other wavelengths, the energy of the applied radiation may be two to six times less than that for conventional treatments, thereby minimizing epidermal damage while still achieving the desired temperature rise in the blood vessels.
  • Further, in accordance with the teachings of this invention, pressure may be utilized to control the depth at which treatment occurs. Thus, if mild pressure is applied to the treatment area, blood will be forced out of the blood vessels in the plexus area, resulting in greater energy absorption at the deeper spider veins, which would be the treatment target, and improving the safety ratio If the pressure is applied to surround the treatment area, blood will be forced into and/or held in the blood vessels in the treatment area, resulting greater energy absorption at the superficial vessels and better treatment of this target. For deeper vessels, additional pressure may be applied to remove blood from the vessels overlying the vessel on which treatment is desired to enhance the safety ratio for such treatment. Cooling may also be utilized to remove blood from upper vessels, particularly plexus vessels.
  • In addition to treatment for removing spider veins or other shallow vascular lesions, the teachings of this invention may also be used to treat port wine stain by destroying the blood vessels causing this condition, and psoriasis by destroying the vascularization in the plexus area which supports the psoriasis plaque, as well as rosacea, telagiecasia, and hemangioma by similar mechanisms in the plexus area. Further, by heating blood vessels of the papillary dermis in general, and the plexus in particular, tissue in the area of these vessels may be heated, for example to approximately 60-70° C. The perturbing of these blood vessels stimulates fibroblasts to be produced, facilitating the growth of new collagen in this area, and thus the removal of wrinkles, scars and other skin blemishes. Heating of the superficial, intermediate and deep veins may also be utilized to either treat the veins themselves, for example to remove the veins, or to heat surrounding tissue to effect some other desired treatment. For example, in addition to treatment of vascular lesions, blood in the vessels can be used as a chromophore for treatment of problems associated with other organs/body components. Rapidly proliferating cells in organs such as hair follicles, sebaceous follicles or glands, pigmented lesions, epidermis, nails and tumors need adequate blood supply, which is provided by well developed vascular systems. Causing damage to the blood supply system or inducing heat diffusion from vessels to the surrounding tissue can trigger other mechanisms to treat such an organ. Superficial and deep arteriovenuos plexuses can be targeted for treatment of skin texture and wrinkles. Heating of vessels in plexuses can cause an inflammatory reaction of surrounding tissue and stimulate influx of fibroblasts for collagen production. As a result, skin texture, wrinkles, and dermis-hypodermis junction and elasticity of skin can be improved. Cellulite can also be reduced by artefiovenuos plexus treatment. Highly vasculated muscular tissue can be treated using the techniques of the present invention in areas of the body with thin skin, particularly above subcutaneous regions (face, neck). As a result, skin lifting and deep wrinkle improvement can be achieved. So, the present invention, in addition to vascular lesion treatment, can be used for hair growth management (reduction and stimulation), acne reduction and prevention, pigmented lesion treatment, skin texture and wrinkles improvement, skin elasticity improvement, cellulite reduction, nail disease treatment, cutaneous tumor treatment, skin lifting, odor production reduction etc.
  • The spot size for treatments employing the teachings of this invention are preferably small, for example in the range between 0.1-1 cm for a laser and 0.1-5 cm for a lamp for vessels at a depth of approximately 1 mm or less, and somewhat larger for deeper vessels. Where blood vessels are being treated, this small spot size can be applied at selected points along the blood vessel to destroy the vessel rather than over the entire vessel, clotting at several points along the vessel normally being sufficient to destroy the vessel.
  • The relationship of pulsewidth τ to thermal relaxation time (TRT) of the vessels should be in the range:

  • 0.1TRT<τ<100TRT.
  • Power and fluence should be sufficient to heat blood in the vessels to a temperature of 50-10° C.
  • While the invention has been particularly shown and described above with reference to preferred embodiments, the foregoing and other changes in form and detail may be made therein by one skilled in the art while still remaining within the spirit and scope of the invention which is to be defined only by the appended claims.

Claims (26)

1. A method for performing dermatological treatments on blood vessels at depths less than about 0.5 mm below a skin surface by applying optical radiation to a treatment area which includes substantial radiation in a blue wavelength band of approximately 380-450 nm.
2. A method as claimed in claim 1 wherein the optical radiation is coherent radiation and is of a wavelength in a range of approximately 400-450 nm.
3. A method as claimed in claim 2 wherein the wavelength of the coherent optical radiation is approximately 420-440 nm.
4. A method as claimed in claim 2 wherein radiation in a green-yellow wavelength band of 500-610 nm is also applied to the treatment area.
5. A method as claimed in claim 1 wherein the optical radiation is non-coherent broadband radiation, and wherein the blue radiation is in a band from 380-450 nm.
6. A method as claimed in claim 5 wherein the radiation has a double band spectrum including approximately 380-450 nm in the blue band and also including approximately 500-610 nm in a green-yellow band.
7. A method as claimed in claim 6 wherein said optical radiation is non-coherent broadband radiation having a triple band spectrum within the approximately 380-450 nm blue band, the approximately 500-610 nm green band and also includes radiation within an NIR band.
8. A method as claimed in claim 1 including applying pressure to a patient's skin to remove blood from blood vessels in an area of treatment above blood vessels for which treatment is desired.
9. A method as claimed in claim 1 including cooling a patient's skin above an area of treatment.
10. A method for performing treatments involving blood vessels by:
providing a broad-band optical radiation source, filtering radiation from said source to pass only wavelengths from said source providing a safety ratio which is approximately at least one, and applying filtered radiation from said source to the blood vessels involved in the treatment.
11. A method as claimed in claim 10 wherein radiation filtered from said source includes radiation having a wavelength from approximately 610 nm to 800 nm.
12. A method as claimed in claim 10 wherein radiation filtered from said source includes radiation having a wavelength from approximately 610 nm to 900 nm
13. A method as claimed in claim 10 wherein radiation filtered from said source includes radiation having a wavelength from approximately 450 nm to 500 nm.
14. A method as claimed in claim 10 wherein radiation filtered from said source includes radiation having a wavelength longer than 1120 nm.
15. A method as claimed in claim 10 including applying pressure to a patient's skin to remove blood from blood vessels in an area of treatment above blood vessels for which treatment is desired.
16. A method as claimed in claim 10 including cooling a patient's skin above an area of treatment.
17. A method as claimed in claim 10 wherein radiation passed during said filtering step includes radiation in a blue wavelength band and radiation in a green-yellow wavelength band, radiation between said bands being filtered out.
18. A method as claimed in claim 17 wherein radiation passed during said filtering step includes radiation in an NIR wavelength band, radiation between said green-yellow band and said NIR band being filtered out.
19. A method as claimed in claim 10 wherein radiation passed during said filtering step includes radiation in a blue wavelength band and radiation in an NIR wavelength band, at least some radiation between said bands being filtered out.
20. A method as claimed in claim 10 wherein radiation passed during said filtering step includes radiation in a green-yellow wavelength band and radiation in an NIR wavelength band, radiation between said bands being filtered out.
21. A method for performing treatments involving blood vessels by:
providing a broad-band optical radiation source, filtering radiation from said source to pass only selected wavelengths from said source which are in at least two of the blue, green-yellow and near infrared (NIR) wavelength bands, at least some of the radiation in wavelengths between the passed radiation bands being filtered out, and applying filtered radiation from said source to the blood vessels involved in the treatment.
22. A method as claimed in claim 21 wherein radiation from all three of said bands are passed during said filtering step.
23. A method for performing treatments involving veins by:
providing a broad-band optical radiation source, filtering radiation from said source to pass only selected wavelengths from said source, the wavelengths and duration of the radiation being selected to provide substantially uniform heating of each vessel, and applying filtered radiation from said source to the vessel involved in the treatment.
24. A method as claimed in claim 23 wherein radiation passed during said filtering step includes radiation in a green-yellow wavelength band and radiation in an NIR wavelength band, radiation between said bands being filtered out.
25. A method as claimed in claim 23 wherein the pulse duration is approximately 0.1 to 100 times the thermal relaxation time of the vessel involved in the treatment.
26-49. (canceled)
US12/210,427 2001-12-27 2008-09-15 Method And Apparatus For Improved Vascular Related Treatment Abandoned US20090149844A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/210,427 US20090149844A1 (en) 2001-12-27 2008-09-15 Method And Apparatus For Improved Vascular Related Treatment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34381101P 2001-12-27 2001-12-27
US10/331,134 US7540869B2 (en) 2001-12-27 2002-12-27 Method and apparatus for improved vascular related treatment
US12/210,427 US20090149844A1 (en) 2001-12-27 2008-09-15 Method And Apparatus For Improved Vascular Related Treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/331,134 Continuation US7540869B2 (en) 2001-12-27 2002-12-27 Method and apparatus for improved vascular related treatment

Publications (1)

Publication Number Publication Date
US20090149844A1 true US20090149844A1 (en) 2009-06-11

Family

ID=23347766

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/331,134 Expired - Lifetime US7540869B2 (en) 2001-12-27 2002-12-27 Method and apparatus for improved vascular related treatment
US12/210,427 Abandoned US20090149844A1 (en) 2001-12-27 2008-09-15 Method And Apparatus For Improved Vascular Related Treatment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/331,134 Expired - Lifetime US7540869B2 (en) 2001-12-27 2002-12-27 Method and apparatus for improved vascular related treatment

Country Status (3)

Country Link
US (2) US7540869B2 (en)
AU (1) AU2002367397A1 (en)
WO (1) WO2003057059A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070073308A1 (en) * 2000-12-28 2007-03-29 Palomar Medical Technologies, Inc. Method and apparatus for EMR treatment
US8915948B2 (en) 2002-06-19 2014-12-23 Palomar Medical Technologies, Llc Method and apparatus for photothermal treatment of tissue at depth
US9028536B2 (en) 2006-08-02 2015-05-12 Cynosure, Inc. Picosecond laser apparatus and methods for its operation and use
US20160114183A1 (en) * 2014-10-24 2016-04-28 The Board Of Trustees Of The University Of Illinois Use of lasers for treating and reversing fibrosis
US20160143692A1 (en) * 2014-11-22 2016-05-26 Candela Corporation Laser System For Skin Treatment
US9780518B2 (en) 2012-04-18 2017-10-03 Cynosure, Inc. Picosecond laser apparatus and methods for treating target tissues with same
US10245107B2 (en) 2013-03-15 2019-04-02 Cynosure, Inc. Picosecond optical radiation systems and methods of use
US10434324B2 (en) 2005-04-22 2019-10-08 Cynosure, Llc Methods and systems for laser treatment using non-uniform output beam
US11418000B2 (en) 2018-02-26 2022-08-16 Cynosure, Llc Q-switched cavity dumped sub-nanosecond laser

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8182473B2 (en) 1999-01-08 2012-05-22 Palomar Medical Technologies Cooling system for a photocosmetic device
US20060149343A1 (en) * 1996-12-02 2006-07-06 Palomar Medical Technologies, Inc. Cooling system for a photocosmetic device
US6508813B1 (en) 1996-12-02 2003-01-21 Palomar Medical Technologies, Inc. System for electromagnetic radiation dermatology and head for use therewith
US6517532B1 (en) 1997-05-15 2003-02-11 Palomar Medical Technologies, Inc. Light energy delivery head
ES2226133T3 (en) * 1997-05-15 2005-03-16 Palomar Medical Technologies, Inc. DERMATOLOGICAL TREATMENT DEVICE.
US6104959A (en) 1997-07-31 2000-08-15 Microwave Medical Corp. Method and apparatus for treating subcutaneous histological features
EP1251791A1 (en) * 2000-01-25 2002-10-30 Palomar Medical Technologies, Inc. Method and apparatus for medical treatment utilizing long duration electromagnetic radiation
US20080172047A1 (en) * 2000-12-28 2008-07-17 Palomar Medical Technologies, Inc. Methods And Devices For Fractional Ablation Of Tissue
US6888319B2 (en) * 2001-03-01 2005-05-03 Palomar Medical Technologies, Inc. Flashlamp drive circuit
JP2004530464A (en) * 2001-03-02 2004-10-07 パロマー・メディカル・テクノロジーズ・インコーポレーテッド Apparatus and method for photocosmetic and photoderma procedures
US20040147984A1 (en) * 2001-11-29 2004-07-29 Palomar Medical Technologies, Inc. Methods and apparatus for delivering low power optical treatments
US7540869B2 (en) * 2001-12-27 2009-06-02 Palomar Medical Technologies, Inc. Method and apparatus for improved vascular related treatment
KR100864720B1 (en) * 2002-04-15 2008-10-23 삼성전자주식회사 Combination system capable of controlling each device through a single OSD menu, and a control method therof
US20070038206A1 (en) * 2004-12-09 2007-02-15 Palomar Medical Technologies, Inc. Photocosmetic device
WO2004000150A1 (en) * 2002-06-19 2003-12-31 Palomar Medical Technologies, Inc. Method and apparatus for photothermal treatment of tissue at depth
WO2004005868A2 (en) * 2002-07-10 2004-01-15 Lockheed Martin Corporation Infrared camera system and method
JP2006501960A (en) * 2002-10-07 2006-01-19 パロマー・メディカル・テクノロジーズ・インコーポレイテッド Apparatus for photobiological stimulation
US20070213792A1 (en) * 2002-10-07 2007-09-13 Palomar Medical Technologies, Inc. Treatment Of Tissue Volume With Radiant Energy
US20070219604A1 (en) * 2006-03-20 2007-09-20 Palomar Medical Technologies, Inc. Treatment of tissue with radiant energy
AU2003284972B2 (en) 2002-10-23 2009-09-10 Palomar Medical Technologies, Inc. Phototreatment device for use with coolants and topical substances
EP1581305A2 (en) * 2002-12-20 2005-10-05 Palomar Medical Technologies, Inc. Apparatus for light treatment of acne and other disorders of follicles
US20050177141A1 (en) * 2003-01-27 2005-08-11 Davenport Scott A. System and method for dermatological treatment gas discharge lamp with controllable current density
US7115127B2 (en) * 2003-02-04 2006-10-03 Cardiodex, Ltd. Methods and apparatus for hemostasis following arterial catheterization
US7223266B2 (en) * 2003-02-04 2007-05-29 Cardiodex Ltd. Methods and apparatus for hemostasis following arterial catheterization
JP2006518266A (en) * 2003-02-19 2006-08-10 パロマー・メディカル・テクノロジーズ・インコーポレイテッド Method and apparatus for treating fake folliculitis
WO2004075721A2 (en) * 2003-02-25 2004-09-10 Spectragenics, Inc. Self-contained, diode-laser-based dermatologic treatment apparatus and metod
US8709003B2 (en) * 2003-02-25 2014-04-29 Tria Beauty, Inc. Capacitive sensing method and device for detecting skin
EP1596707A4 (en) * 2003-02-25 2010-08-18 Tria Beauty Inc Acne treatment device and method
JP4361081B2 (en) * 2003-02-25 2009-11-11 トリア ビューティ インコーポレイテッド Eye-safe dermatological treatment device
US7250045B2 (en) * 2003-02-25 2007-07-31 Spectragenics, Inc. Self-contained, eye-safe hair-regrowth-inhibition apparatus and method
US7981111B2 (en) 2003-02-25 2011-07-19 Tria Beauty, Inc. Method and apparatus for the treatment of benign pigmented lesions
US7413567B2 (en) * 2003-02-25 2008-08-19 Spectragenics, Inc. Optical sensor and method for identifying the presence of skin
EP2604216B1 (en) 2003-02-25 2018-08-22 Tria Beauty, Inc. Self-contained, diode-laser-based dermatologic treatment apparatus
WO2004080279A2 (en) * 2003-03-06 2004-09-23 Spectragenics, Inc. In the patent cooperation treaty application for patent
US7153298B1 (en) * 2003-03-28 2006-12-26 Vandolay, Inc. Vascular occlusion systems and methods
US7291140B2 (en) * 2003-07-18 2007-11-06 Cutera, Inc. System and method for low average power dermatologic light treatment device
US8915906B2 (en) * 2003-08-25 2014-12-23 Cutera, Inc. Method for treatment of post-partum abdominal skin redundancy or laxity
US7722600B2 (en) 2003-08-25 2010-05-25 Cutera, Inc. System and method for heating skin using light to provide tissue treatment
US8870856B2 (en) 2003-08-25 2014-10-28 Cutera, Inc. Method for heating skin using light to provide tissue treatment
AU2003296194A1 (en) * 2003-12-03 2005-06-24 Thomas Chen Blood vessel seeking method and vein seeking device
US7326199B2 (en) * 2003-12-22 2008-02-05 Cutera, Inc. System and method for flexible architecture for dermatologic treatments utilizing multiple light sources
US7220254B2 (en) * 2003-12-31 2007-05-22 Palomar Medical Technologies, Inc. Dermatological treatment with visualization
US8777935B2 (en) 2004-02-25 2014-07-15 Tria Beauty, Inc. Optical sensor and method for identifying the presence of skin
AU2005231443B2 (en) 2004-04-01 2012-02-23 The General Hospital Corporation Method and apparatus for dermatological treatment and tissue reshaping
US20080132886A1 (en) * 2004-04-09 2008-06-05 Palomar Medical Technologies, Inc. Use of fractional emr technology on incisions and internal tissues
CA2561344A1 (en) * 2004-04-09 2005-10-27 Palomar Medical Technologies, Inc. Methods and products for producing lattices of emr-treated islets in tissues, and uses therefor
EP1781329B1 (en) * 2004-08-06 2013-07-31 Syneron Beauty Ltd. Therapy device
US20060047281A1 (en) * 2004-09-01 2006-03-02 Syneron Medical Ltd. Method and system for invasive skin treatment
FR2878185B1 (en) * 2004-11-22 2008-11-07 Sidel Sas PROCESS FOR MANUFACTURING CONTAINERS COMPRISING A HEATING STEP BY MEANS OF A COHERENT ELECTROMAGNETIC RADIATION BEAM
CA2587228A1 (en) * 2004-11-22 2006-05-26 Cardiodex Ltd. Techniques for heat-treating varicose veins
US10857722B2 (en) * 2004-12-03 2020-12-08 Pressco Ip Llc Method and system for laser-based, wavelength specific infrared irradiation treatment
US7425296B2 (en) * 2004-12-03 2008-09-16 Pressco Technology Inc. Method and system for wavelength specific thermal irradiation and treatment
US20110015549A1 (en) * 2005-01-13 2011-01-20 Shimon Eckhouse Method and apparatus for treating a diseased nail
EP1858588A2 (en) * 2005-02-18 2007-11-28 Palomar Medical Technologies, Inc. Dermatological treatment device
US20060253176A1 (en) * 2005-02-18 2006-11-09 Palomar Medical Technologies, Inc. Dermatological treatment device with deflector optic
JP2009509140A (en) 2005-09-15 2009-03-05 パロマー・メデイカル・テクノロジーズ・インコーポレーテツド Skin optical determination device
US20070194717A1 (en) * 2006-02-17 2007-08-23 Palomar Medical Technologies, Inc. Lamp for use in a tissue treatment device
US20070244371A1 (en) * 2006-04-04 2007-10-18 Nguyen Hoa D Phlebectomy illumination device and methods
US20070255355A1 (en) * 2006-04-06 2007-11-01 Palomar Medical Technologies, Inc. Apparatus and method for skin treatment with compression and decompression
ITFI20060307A1 (en) * 2006-12-05 2008-06-06 Light 4 Tech Firenze S R L DEVICE BASED ON LED TECHNOLOGY FOR THE BLOOD VASE OF HEMOSTASIS
EP1935452A1 (en) * 2006-12-19 2008-06-25 Koninklijke Philips Electronics N.V. Electrochromic device and photodynamic treatment device comprising such an electrochromic device
WO2008095176A1 (en) * 2007-02-01 2008-08-07 Candela Corporation Light beam wavelength mixing for treating various dermatologic conditions
FR2913210B1 (en) * 2007-03-02 2009-05-29 Sidel Participations IMPROVEMENTS IN THE HEATING OF PLASTIC MATERIALS BY INFRARED RADIATION
US20100211059A1 (en) 2007-04-19 2010-08-19 Deem Mark E Systems and methods for creating an effect using microwave energy to specified tissue
CN101711134B (en) 2007-04-19 2016-08-17 米勒玛尔实验室公司 Tissue is applied the system of microwave energy and in organized layer, produces the system of tissue effect
WO2008131302A2 (en) 2007-04-19 2008-10-30 The Foundry, Inc. Methods and apparatus for reducing sweat production
JP2010524589A (en) 2007-04-19 2010-07-22 ザ ファウンドリー, インコーポレイテッド Method, apparatus and system for non-invasive delivery of microwave therapy
WO2009128940A1 (en) 2008-04-17 2009-10-22 Miramar Labs, Inc. Systems, apparatus, methods and procedures for the noninvasive treatment of tissue using microwave energy
JP2010526645A (en) 2007-05-11 2010-08-05 クラリメディックス・インコーポレイテッド Visible light regulation of mitochondrial function in hypoxia and disease
KR20100029235A (en) * 2007-06-08 2010-03-16 싸이노슈어, 인코포레이티드 Surgical waveguide
FR2917005B1 (en) * 2007-06-11 2009-08-28 Sidel Participations HEATING FACILITY FOR PREFORMING BODIES FOR BLOWING CONTAINERS
US8366706B2 (en) 2007-08-15 2013-02-05 Cardiodex, Ltd. Systems and methods for puncture closure
US8920409B2 (en) * 2007-10-04 2014-12-30 Cutera, Inc. System and method for dermatological lesion treatment using gas discharge lamp with controllable current density
JP6008463B2 (en) * 2007-12-07 2016-10-19 ザ ジェネラル ホスピタル コーポレイション System and apparatus for dermatological treatment
EP3391846B1 (en) 2007-12-12 2022-07-27 miraDry, Inc. Systems and apparatus for the noninvasive treatment of tissue using microwave energy
BRPI0820706B8 (en) 2007-12-12 2021-06-22 Miramar Labs Inc disposable medical device for use with an applicator
DE202009017814U1 (en) 2008-01-17 2010-07-01 Syneron Medical Ltd. Hair removal device for personal use
KR20100115748A (en) 2008-01-24 2010-10-28 시네론 메디컬 리미티드 A device, apparatus, and method of adipose tissue treatment
EP2252229B1 (en) * 2008-03-11 2012-12-05 Shaser, Inc. Enhancing optical radiation systems used in dermatologic treatments
US9687671B2 (en) * 2008-04-25 2017-06-27 Channel Investments, Llc Optical sensor and method for identifying the presence of skin and the pigmentation of skin
US9314293B2 (en) * 2008-07-16 2016-04-19 Syneron Medical Ltd RF electrode for aesthetic and body shaping devices and method of using same
US20100017750A1 (en) * 2008-07-16 2010-01-21 Avner Rosenberg User interface
US8778003B2 (en) * 2008-09-21 2014-07-15 Syneron Medical Ltd Method and apparatus for personal skin treatment
US20120065709A1 (en) * 2008-09-30 2012-03-15 The Regents Of The University Of Colorado Methods and devices for visible light modulation of mitochondrial function in hypoxia and disease
US8606366B2 (en) 2009-02-18 2013-12-10 Syneron Medical Ltd. Skin treatment apparatus for personal use and method for using same
EP2730313A1 (en) 2009-02-25 2014-05-14 Syneron Medical Ltd. Electrical skin rejuvenation
US20100241038A1 (en) * 2009-03-20 2010-09-23 Bwt Property, Inc. Phototherapy Method for Assisting Transvenous Lead Placement
US20100280328A1 (en) * 2009-05-01 2010-11-04 Tyco Healthcare Group, Lp Methods and systems for illumination during phlebectomy procedures
US9919168B2 (en) 2009-07-23 2018-03-20 Palomar Medical Technologies, Inc. Method for improvement of cellulite appearance
KR101784536B1 (en) 2009-12-06 2017-11-06 시네론 메디컬 리미티드 A method and apparatus for personal skin treatment
ITFI20110015A1 (en) * 2011-01-25 2012-07-26 El En Spa "DEVICE AND METHOD FOR THE APPLICATION OF OPTICAL RADIATION TO A TARGET"
US9314301B2 (en) 2011-08-01 2016-04-19 Miramar Labs, Inc. Applicator and tissue interface module for dermatological device
JP6094963B2 (en) * 2013-02-22 2017-03-15 パナソニックIpマネジメント株式会社 Light beauty equipment for body hair
JP2014161455A (en) 2013-02-22 2014-09-08 Panasonic Corp Cosmetic apparatus for hair
US10779885B2 (en) 2013-07-24 2020-09-22 Miradry. Inc. Apparatus and methods for the treatment of tissue using microwave energy
US10518104B2 (en) 2015-04-23 2019-12-31 Cynosure, Llc Systems and methods of unattended treatment
US10737109B2 (en) 2015-04-23 2020-08-11 Cynosure, Llc Systems and methods of unattended treatment of a subject's head or neck
BR112019010363A2 (en) 2016-11-22 2019-08-27 Dominion Aesthetic Tech Inc systems and methods for aesthetic treatment
GB201702098D0 (en) * 2017-02-08 2017-03-22 Michelson Diagnostics Ltd Processing optical coherence tomography (OCT) scans

Citations (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1706161A (en) * 1926-11-13 1929-03-19 Gen Electric Illuminating unit
US2472385A (en) * 1946-07-18 1949-06-07 Michael A Rollman Massage device
US3327712A (en) * 1961-09-15 1967-06-27 Ira H Kaufman Photocoagulation type fiber optical surgical device
US3486070A (en) * 1968-04-29 1969-12-23 Westinghouse Electric Corp Solid-state constant power ballast for electric discharge device
US3527932A (en) * 1967-11-16 1970-09-08 James J Thomas Transilluminating flashlight
US3538919A (en) * 1967-04-07 1970-11-10 Gregory System Inc Depilation by means of laser energy
US3597652A (en) * 1969-01-14 1971-08-03 Eg & G Inc Apparatus for maintaining the temperature and operating a calibrated lamp in a constant resistance mode
US3622743A (en) * 1969-04-28 1971-11-23 Hrand M Muncheryan Laser eraser and microwelder
US3693623A (en) * 1970-12-25 1972-09-26 Gregory System Inc Photocoagulation means and method for depilation
US3818914A (en) * 1972-04-17 1974-06-25 Spectroderm Inc Apparatus and method for treatment of skin disorders
US3834391A (en) * 1973-01-19 1974-09-10 Block Carol Ltd Method and apparatus for photoepilation
US3846811A (en) * 1972-03-29 1974-11-05 Canon Kk Flash unit for use with camera
US3857015A (en) * 1972-11-08 1974-12-24 O Richardson Electrically heated heat sealing implement
US3900034A (en) * 1974-04-10 1975-08-19 Us Energy Photochemical stimulation of nerves
US4233493A (en) * 1974-05-21 1980-11-11 Nath Guenther Apparatus for applying intense light radiation to a limited area
US4273109A (en) * 1976-07-06 1981-06-16 Cavitron Corporation Fiber optic light delivery apparatus and medical instrument utilizing same
US4275335A (en) * 1979-03-28 1981-06-23 Minolta Camera Kabushiki Kaisha Constant light intensity electronic flash device
US4316467A (en) * 1980-06-23 1982-02-23 Lorenzo P. Maun Control for laser hemangioma treatment system
US4388924A (en) * 1981-05-21 1983-06-21 Weissman Howard R Method for laser depilation
US4456872A (en) * 1969-10-27 1984-06-26 Bose Corporation Current controlled two-state modulation
US4461294A (en) * 1982-01-20 1984-07-24 Baron Neville A Apparatus and process for recurving the cornea of an eye
US4524289A (en) * 1983-04-11 1985-06-18 Xerox Corporation Flash lamp power supply with reduced capacitance requirements
US4539987A (en) * 1980-02-27 1985-09-10 Nath Guenther Apparatus for coagulation by heat radiation
US4561440A (en) * 1981-11-18 1985-12-31 Matsushita Electric Industrial Co., Ltd. Apparatus for laser light medical treatment
US4591762A (en) * 1983-05-31 1986-05-27 Olympus Optical, Co. Electronic flash
US4608978A (en) * 1983-09-26 1986-09-02 Carol Block Limited Method and apparatus for photoepiltion
US4617926A (en) * 1982-07-09 1986-10-21 Sutton A Gunilla Depilation device and method
US4695697A (en) * 1985-12-13 1987-09-22 Gv Medical, Inc. Fiber tip monitoring and protection assembly
US4718416A (en) * 1984-01-13 1988-01-12 Kabushiki Kaisha Toshiba Laser treatment apparatus
US4733660A (en) * 1984-08-07 1988-03-29 Medical Laser Research And Development Corporation Laser system for providing target specific energy deposition and damage
US4745909A (en) * 1987-05-15 1988-05-24 Pelton Robert J Cold massage tool and method of use thereof
US4747660A (en) * 1983-08-12 1988-05-31 Olympus Optical Co., Ltd. Light transmitter
US4749913A (en) * 1987-04-17 1988-06-07 General Electric Company Operating circuit for a direct current discharge lamp
US4819669A (en) * 1985-03-29 1989-04-11 Politzer Eugene J Method and apparatus for shaving the beard
US4832024A (en) * 1986-04-29 1989-05-23 Georges Boussignac Cardio-vascular catheter for shooting a laser beam
US4860172A (en) * 1988-01-19 1989-08-22 Biotronics Associates, Inc. Lamp-based laser simulator
US4860744A (en) * 1987-11-02 1989-08-29 Raj K. Anand Thermoelectrically controlled heat medical catheter
US4884560A (en) * 1988-07-11 1989-12-05 Kuracina Thomas C Thermal massage device
US4905690A (en) * 1986-06-30 1990-03-06 Medical Laser Research Co., Ltd. Semiconductor laser treatment device
US4917084A (en) * 1985-07-31 1990-04-17 C. R. Bard, Inc. Infrared laser catheter system
US4926227A (en) * 1986-08-01 1990-05-15 Nanometrics Inc. Sensor devices with internal packaged coolers
US4928038A (en) * 1988-09-26 1990-05-22 General Electric Company Power control circuit for discharge lamp and method of operating same
US4930504A (en) * 1987-11-13 1990-06-05 Diamantopoulos Costas A Device for biostimulation of tissue and method for treatment of tissue
US4945239A (en) * 1989-03-29 1990-07-31 Center For Innovative Technology Early detection of breast cancer using transillumination
US5000752A (en) * 1985-12-13 1991-03-19 William J. Hoskin Treatment apparatus and method
US5057104A (en) * 1989-05-30 1991-10-15 Cyrus Chess Method and apparatus for treating cutaneous vascular lesions
US5059192A (en) * 1990-04-24 1991-10-22 Nardo Zaias Method of hair depilation
US5065515A (en) * 1991-01-24 1991-11-19 Warner-Lambert Company Thermally assisted shaving system
US5071417A (en) * 1990-06-15 1991-12-10 Rare Earth Medical Lasers, Inc. Laser fusion of biological materials
US5108388A (en) * 1983-12-15 1992-04-28 Visx, Incorporated Laser surgery method
US20020128695A1 (en) * 1999-07-07 2002-09-12 Yoram Harth Apparatus and method for high energy photodynamic therapy of acne vulgaris and seborrhea
US20020173780A1 (en) * 2001-03-02 2002-11-21 Altshuler Gregory B. Apparatus and method for photocosmetic and photodermatological treatment
US7540869B2 (en) * 2001-12-27 2009-06-02 Palomar Medical Technologies, Inc. Method and apparatus for improved vascular related treatment

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140984A (en) 1983-10-06 1992-08-25 Proclosure, Inc. Laser healing method and apparatus
US5196004A (en) 1985-07-31 1993-03-23 C. R. Bard, Inc. Infrared laser catheter system
US5137530A (en) 1985-09-27 1992-08-11 Sand Bruce J Collagen treatment apparatus
US5242437A (en) 1988-06-10 1993-09-07 Trimedyne Laser Systems, Inc. Medical device applying localized high intensity light and heat, particularly for destruction of the endometrium
US5263951A (en) 1989-04-21 1993-11-23 Kerus Medical Systems Correction of the optical focusing system of the eye using laser thermal keratoplasty
US5486172A (en) 1989-05-30 1996-01-23 Chess; Cyrus Apparatus for treating cutaneous vascular lesions
US5182557A (en) 1989-09-20 1993-01-26 Semborg Recrob, Corp. Motorized joystick
DE3936367A1 (en) 1989-11-02 1991-05-08 Simon Pal SHAVER
FR2655849B1 (en) 1989-12-19 1997-10-31 Raymond Bontemps LOCAL CRYOGENIC DEVICE FOR MASSAGE OF THE SKIN.
JPH05505737A (en) * 1990-03-14 1993-08-26 キャンデラ・コーポレーション Apparatus and method for treating pigmented lesions using pulsed radiation
SE465953B (en) 1990-04-09 1991-11-25 Morgan Gustafsson DEVICE FOR TREATMENT OF UNDESECTED EXTERNAL ACCOMMODATIONS
US5549660A (en) 1990-11-15 1996-08-27 Amron, Ltd. Method of treating acne
US5300097A (en) 1991-02-13 1994-04-05 Lerner Ethan A Fiber optic psoriasis treatment device
US5207671A (en) 1991-04-02 1993-05-04 Franken Peter A Laser debridement of wounds
US5474549A (en) 1991-07-09 1995-12-12 Laserscope Method and system for scanning a laser beam for controlled distribution of laser dosage
US5178617A (en) 1991-07-09 1993-01-12 Laserscope System for controlled distribution of laser dosage
US5225926A (en) 1991-09-04 1993-07-06 International Business Machines Corporation Durable optical elements fabricated from free standing polycrystalline diamond and non-hydrogenated amorphous diamond like carbon (dlc) thin films
US5267399A (en) 1991-09-09 1993-12-07 Johnston William A Implement for simultaneous skin chilling and chilled gel application
US5370642A (en) 1991-09-25 1994-12-06 Keller; Gregory S. Method of laser cosmetic surgery
US5226907A (en) 1991-10-29 1993-07-13 Tankovich Nikolai I Hair removal device and method
US5871480A (en) * 1991-10-29 1999-02-16 Thermolase Corporation Hair removal using photosensitizer and laser
US5817089A (en) * 1991-10-29 1998-10-06 Thermolase Corporation Skin treatment process using laser
US5425728A (en) 1991-10-29 1995-06-20 Tankovich; Nicolai I. Hair removal device and method
US5344418A (en) 1991-12-12 1994-09-06 Shahriar Ghaffari Optical system for treatment of vascular lesions
US5275596A (en) 1991-12-23 1994-01-04 Laser Centers Of America Laser energy delivery tip element with throughflow of vaporized materials
IL100545A (en) 1991-12-29 1995-03-15 Dimotech Ltd Apparatus for photodynamic therapy treatment
US5405368A (en) 1992-10-20 1995-04-11 Esc Inc. Method and apparatus for therapeutic electromagnetic treatment
US5334191A (en) 1992-05-21 1994-08-02 Dix Phillip Poppas Laser tissue welding control system
DE69311478T2 (en) 1992-09-07 1998-01-02 Philips Electronics Nv Method for producing a block-shaped carrier body for a semiconductor component
US5626631A (en) 1992-10-20 1997-05-06 Esc Medical Systems Ltd. Method and apparatus for therapeutic electromagnetic treatment
US5683380A (en) * 1995-03-29 1997-11-04 Esc Medical Systems Ltd. Method and apparatus for depilation using pulsed electromagnetic radiation
US5620478A (en) 1992-10-20 1997-04-15 Esc Medical Systems Ltd. Method and apparatus for therapeutic electromagnetic treatment
US6280438B1 (en) * 1992-10-20 2001-08-28 Esc Medical Systems Ltd. Method and apparatus for electromagnetic treatment of the skin, including hair depilation
US5720772A (en) * 1992-10-20 1998-02-24 Esc Medical Systems Ltd. Method and apparatus for therapeutic electromagnetic treatment
US5334193A (en) 1992-11-13 1994-08-02 American Cardiac Ablation Co., Inc. Fluid cooled ablation catheter
US5342358A (en) 1993-01-12 1994-08-30 S.L.T. Japan Co., Ltd. Apparatus for operation by laser energy
US5707403A (en) * 1993-02-24 1998-01-13 Star Medical Technologies, Inc. Method for the laser treatment of subsurface blood vessels
US5304170A (en) 1993-03-12 1994-04-19 Green Howard A Method of laser-induced tissue necrosis in carotenoid-containing skin structures
US5350376A (en) 1993-04-16 1994-09-27 Ceramoptec, Inc. Optical controller device
US5403306A (en) 1993-06-22 1995-04-04 Vanderbilt University Laser surgery method
US5860967A (en) * 1993-07-21 1999-01-19 Lucid, Inc. Dermatological laser treatment system with electronic visualization of the area being treated
US5415654A (en) 1993-10-05 1995-05-16 S.L.T. Japan Co., Ltd. Laser balloon catheter apparatus
US5458140A (en) * 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5885211A (en) * 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5413587A (en) 1993-11-22 1995-05-09 Hochstein; Peter A. Infrared heating apparatus and methods
US5358503A (en) 1994-01-25 1994-10-25 Bertwell Dale E Photo-thermal therapeutic device and method
US5616140A (en) 1994-03-21 1997-04-01 Prescott; Marvin Method and apparatus for therapeutic laser treatment
US5505726A (en) 1994-03-21 1996-04-09 Dusa Pharmaceuticals, Inc. Article of manufacture for the photodynamic therapy of dermal lesion
US5519534A (en) 1994-05-25 1996-05-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Irradiance attachment for an optical fiber to provide a uniform level of illumination across a plane
US5531740A (en) 1994-09-06 1996-07-02 Rapistan Demag Corporation Automatic color-activated scanning treatment of dermatological conditions by laser
US5531739A (en) 1994-09-23 1996-07-02 Coherent, Inc. Method of treating veins
US5522813A (en) 1994-09-23 1996-06-04 Coherent, Inc. Method of treating veins
US5735884A (en) * 1994-10-04 1998-04-07 Medtronic, Inc. Filtered feedthrough assembly for implantable medical device
US5571098A (en) * 1994-11-01 1996-11-05 The General Hospital Corporation Laser surgical devices
AT403654B (en) * 1994-12-01 1998-04-27 Binder Michael Dr DEVICE FOR THE OPTICAL EXAMINATION OF HUMAN SKIN AND THE SAME ASSIGNMENT EVALUATION DEVICE
US5558667A (en) 1994-12-14 1996-09-24 Coherent, Inc. Method and apparatus for treating vascular lesions
US5735844A (en) * 1995-02-01 1998-04-07 The General Hospital Corporation Hair removal using optical pulses
US5595568A (en) 1995-02-01 1997-01-21 The General Hospital Corporation Permanent hair removal using optical pulses
US5868731A (en) * 1996-03-04 1999-02-09 Innotech Usa, Inc. Laser surgical device and method of its use
US5885273A (en) * 1995-03-29 1999-03-23 Esc Medical Systems, Ltd. Method for depilation using pulsed electromagnetic radiation
US5658148A (en) 1995-04-26 1997-08-19 Ceramoptec Industries, Inc. Dental laser brushing or cleaning device
DE29508077U1 (en) * 1995-05-16 1995-08-10 Wilden Lutz Dr Med Oral care device
US5658323A (en) 1995-07-12 1997-08-19 Miller; Iain D. Method and apparatus for dermatology treatment
US5879376A (en) * 1995-07-12 1999-03-09 Luxar Corporation Method and apparatus for dermatology treatment
US6350276B1 (en) * 1996-01-05 2002-02-26 Thermage, Inc. Tissue remodeling apparatus containing cooling fluid
US5630811A (en) 1996-03-25 1997-05-20 Miller; Iain D. Method and apparatus for hair removal
US5742392A (en) * 1996-04-16 1998-04-21 Seymour Light, Inc. Polarized material inspection apparatus
US5655547A (en) 1996-05-15 1997-08-12 Esc Medical Systems Ltd. Method for laser surgery
US5743901A (en) * 1996-05-15 1998-04-28 Star Medical Technologies, Inc. High fluence diode laser device and method for the fabrication and use thereof
ES2200187T3 (en) * 1996-07-03 2004-03-01 Altea Therapeutics Corporation MULTIPLE MECHANICAL MICROPORATION OF THE SKIN OR MUCOSA.
US6096029A (en) * 1997-02-24 2000-08-01 Laser Skin Toner, Inc. Laser method for subsurface cutaneous treatment
US6214034B1 (en) * 1996-09-04 2001-04-10 Radiancy, Inc. Method of selective photothermolysis
DE69626136T2 (en) * 1996-09-10 2003-10-09 Grigory Borisovic Altshuler TOOTHBRUSH
US6517532B1 (en) * 1997-05-15 2003-02-11 Palomar Medical Technologies, Inc. Light energy delivery head
US6015404A (en) * 1996-12-02 2000-01-18 Palomar Medical Technologies, Inc. Laser dermatology with feedback control
US6653618B2 (en) * 2000-04-28 2003-11-25 Palomar Medical Technologies, Inc. Contact detecting method and apparatus for an optical radiation handpiece
US6508813B1 (en) * 1996-12-02 2003-01-21 Palomar Medical Technologies, Inc. System for electromagnetic radiation dermatology and head for use therewith
US7204832B2 (en) * 1996-12-02 2007-04-17 Pálomar Medical Technologies, Inc. Cooling system for a photo cosmetic device
US6050990A (en) * 1996-12-05 2000-04-18 Thermolase Corporation Methods and devices for inhibiting hair growth and related skin treatments
US5830208A (en) * 1997-01-31 1998-11-03 Laserlite, Llc Peltier cooled apparatus and methods for dermatological treatment
US5891063A (en) * 1997-04-03 1999-04-06 Vigil; Arlene Skin rejuvinating system
ES2226133T3 (en) * 1997-05-15 2005-03-16 Palomar Medical Technologies, Inc. DERMATOLOGICAL TREATMENT DEVICE.
US6030399A (en) * 1997-06-04 2000-02-29 Spectrx, Inc. Fluid jet blood sampling device and methods
US5883471A (en) * 1997-06-20 1999-03-16 Polycom, Inc. Flashlamp pulse shaper and method
US5885274A (en) * 1997-06-24 1999-03-23 New Star Lasers, Inc. Filament lamp for dermatological treatment
US6176854B1 (en) * 1997-10-08 2001-01-23 Robert Roy Cone Percutaneous laser treatment
FR2772274B1 (en) * 1997-12-16 2002-01-04 Galderma Rech Dermatologique DEVICE COMPRISING A CHROMOPHORE COMPOSITION FOR APPLICATION ON THE SKIN, METHOD FOR MANUFACTURING SUCH A DEVICE AND USES THEREOF
IL122840A (en) * 1997-12-31 2002-04-21 Radiancy Inc Apparatus and methods for removing hair
WO1999034868A1 (en) * 1998-01-07 1999-07-15 Kim Robin Segal Diode laser irradiation and electrotherapy system for biological tissue stimulation
US7048731B2 (en) * 1998-01-23 2006-05-23 Laser Abrasive Technologies, Llc Methods and apparatus for light induced processing of biological tissues and of dental materials
US6162055A (en) * 1998-02-13 2000-12-19 Britesmile, Inc. Light activated tooth whitening composition and method of using same
US6530915B1 (en) * 1998-03-06 2003-03-11 Spectrx, Inc. Photothermal structure for biomedical applications, and method therefor
US6022316A (en) * 1998-03-06 2000-02-08 Spectrx, Inc. Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications
US6173202B1 (en) * 1998-03-06 2001-01-09 Spectrx, Inc. Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue
ES2403359T3 (en) * 1998-03-27 2013-05-17 The General Hospital Corporation Procedure and apparatus for the selective determination of lipid rich tissues
US6223071B1 (en) * 1998-05-01 2001-04-24 Dusa Pharmaceuticals Inc. Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
US6595986B2 (en) * 1998-10-15 2003-07-22 Stephen Almeida Multiple pulse photo-dermatological device
US6663659B2 (en) * 2000-01-13 2003-12-16 Mcdaniel David H. Method and apparatus for the photomodulation of living cells
US6936044B2 (en) * 1998-11-30 2005-08-30 Light Bioscience, Llc Method and apparatus for the stimulation of hair growth
US6514242B1 (en) * 1998-12-03 2003-02-04 David Vasily Method and apparatus for laser removal of hair
US6183500B1 (en) * 1998-12-03 2001-02-06 Sli Lichtsysteme Gmbh Process and apparatus for the cosmetic treatment of acne vulgaris
US6183773B1 (en) * 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
SE522249C2 (en) * 1999-01-13 2004-01-27 Biolight Patent Holding Ab Control device for controlling external processing by light
WO2000044294A1 (en) * 1999-01-29 2000-08-03 Welch Allyn, Inc. Apparatus and method of photo-specific tissue treatment
AU3147200A (en) * 1999-03-08 2000-09-28 Asah Medico A/S An apparatus for tissue treatment and having a monitor for display of tissue features
US6709269B1 (en) * 2000-04-14 2004-03-23 Gregory B. Altshuler Apparatus and method for the processing of solid materials, including hard tissues
US6685699B1 (en) * 1999-06-09 2004-02-03 Spectrx, Inc. Self-removing energy absorbing structure for thermal tissue ablation
US20040122492A1 (en) * 1999-07-07 2004-06-24 Yoram Harth Phototherapeutic treatment of skin conditions
US6210425B1 (en) * 1999-07-08 2001-04-03 Light Sciences Corporation Combined imaging and PDT delivery system
US6354370B1 (en) * 1999-12-16 2002-03-12 The United States Of America As Represented By The Secretary Of The Air Force Liquid spray phase-change cooling of laser devices
AU2001257069A1 (en) * 2000-04-17 2001-10-30 Medelaser, Llc Photostimulaton treatment apparatus and methods for use
KR100496838B1 (en) * 2000-09-18 2005-06-22 쟈트코 가부시키가이샤 Shift Control System for Automatic Transmission
US20020149326A1 (en) * 2001-03-01 2002-10-17 Mikhail Inochkin Flashlamp drive circuit
US6679837B2 (en) * 2001-06-01 2004-01-20 Intlas Ltd. Laser light irradiation apparatus
US6723090B2 (en) * 2001-07-02 2004-04-20 Palomar Medical Technologies, Inc. Fiber laser device for medical/cosmetic procedures
US20030032900A1 (en) * 2001-08-08 2003-02-13 Engii (2001) Ltd. System and method for facial treatment
US20030036680A1 (en) * 2001-08-15 2003-02-20 Michael Black Method and apparatus for thermal ablation of biological tissue using a scanning laser beam with real-time video monitoring and monitoring of therapeutic treatment parameters
US20040082940A1 (en) * 2002-10-22 2004-04-29 Michael Black Dermatological apparatus and method
IL163946A0 (en) * 2002-03-12 2005-12-18 Gen Hospital Corp Method and apparatus for hair growth managment
AU2003226326A1 (en) * 2002-04-09 2003-10-27 Altshuler, Gregory Method and apparatus for processing hard material
WO2004000098A2 (en) * 2002-06-19 2003-12-31 Palomar Medical Technologies, Inc. Method and apparatus for treatment of cutaneous and subcutaneous conditions
EP1653876A1 (en) * 2003-07-11 2006-05-10 Reliant Technologies, Inc. Method and apparatus for fractional photo therapy of skin
US8870856B2 (en) * 2003-08-25 2014-10-28 Cutera, Inc. Method for heating skin using light to provide tissue treatment
US7041100B2 (en) * 2004-01-21 2006-05-09 Syneron Medical Ltd. Method and system for selective electro-thermolysis of skin targets

Patent Citations (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1706161A (en) * 1926-11-13 1929-03-19 Gen Electric Illuminating unit
US2472385A (en) * 1946-07-18 1949-06-07 Michael A Rollman Massage device
US3327712A (en) * 1961-09-15 1967-06-27 Ira H Kaufman Photocoagulation type fiber optical surgical device
US3538919A (en) * 1967-04-07 1970-11-10 Gregory System Inc Depilation by means of laser energy
US3527932A (en) * 1967-11-16 1970-09-08 James J Thomas Transilluminating flashlight
US3486070A (en) * 1968-04-29 1969-12-23 Westinghouse Electric Corp Solid-state constant power ballast for electric discharge device
US3597652A (en) * 1969-01-14 1971-08-03 Eg & G Inc Apparatus for maintaining the temperature and operating a calibrated lamp in a constant resistance mode
US3622743A (en) * 1969-04-28 1971-11-23 Hrand M Muncheryan Laser eraser and microwelder
US4456872A (en) * 1969-10-27 1984-06-26 Bose Corporation Current controlled two-state modulation
US3693623A (en) * 1970-12-25 1972-09-26 Gregory System Inc Photocoagulation means and method for depilation
US3846811A (en) * 1972-03-29 1974-11-05 Canon Kk Flash unit for use with camera
US3818914A (en) * 1972-04-17 1974-06-25 Spectroderm Inc Apparatus and method for treatment of skin disorders
US3857015A (en) * 1972-11-08 1974-12-24 O Richardson Electrically heated heat sealing implement
US3834391A (en) * 1973-01-19 1974-09-10 Block Carol Ltd Method and apparatus for photoepilation
US3900034A (en) * 1974-04-10 1975-08-19 Us Energy Photochemical stimulation of nerves
US4233493A (en) * 1974-05-21 1980-11-11 Nath Guenther Apparatus for applying intense light radiation to a limited area
US4273109A (en) * 1976-07-06 1981-06-16 Cavitron Corporation Fiber optic light delivery apparatus and medical instrument utilizing same
US4275335A (en) * 1979-03-28 1981-06-23 Minolta Camera Kabushiki Kaisha Constant light intensity electronic flash device
US4539987A (en) * 1980-02-27 1985-09-10 Nath Guenther Apparatus for coagulation by heat radiation
US4316467A (en) * 1980-06-23 1982-02-23 Lorenzo P. Maun Control for laser hemangioma treatment system
US4388924A (en) * 1981-05-21 1983-06-21 Weissman Howard R Method for laser depilation
US4561440A (en) * 1981-11-18 1985-12-31 Matsushita Electric Industrial Co., Ltd. Apparatus for laser light medical treatment
US4461294A (en) * 1982-01-20 1984-07-24 Baron Neville A Apparatus and process for recurving the cornea of an eye
US4617926A (en) * 1982-07-09 1986-10-21 Sutton A Gunilla Depilation device and method
US4524289A (en) * 1983-04-11 1985-06-18 Xerox Corporation Flash lamp power supply with reduced capacitance requirements
US4591762A (en) * 1983-05-31 1986-05-27 Olympus Optical, Co. Electronic flash
US4747660A (en) * 1983-08-12 1988-05-31 Olympus Optical Co., Ltd. Light transmitter
US4608978A (en) * 1983-09-26 1986-09-02 Carol Block Limited Method and apparatus for photoepiltion
US5108388B1 (en) * 1983-12-15 2000-09-19 Visx Inc Laser surgery method
US5108388A (en) * 1983-12-15 1992-04-28 Visx, Incorporated Laser surgery method
US4718416A (en) * 1984-01-13 1988-01-12 Kabushiki Kaisha Toshiba Laser treatment apparatus
US4733660A (en) * 1984-08-07 1988-03-29 Medical Laser Research And Development Corporation Laser system for providing target specific energy deposition and damage
US4819669A (en) * 1985-03-29 1989-04-11 Politzer Eugene J Method and apparatus for shaving the beard
US4917084A (en) * 1985-07-31 1990-04-17 C. R. Bard, Inc. Infrared laser catheter system
US4695697A (en) * 1985-12-13 1987-09-22 Gv Medical, Inc. Fiber tip monitoring and protection assembly
US5000752A (en) * 1985-12-13 1991-03-19 William J. Hoskin Treatment apparatus and method
US4832024A (en) * 1986-04-29 1989-05-23 Georges Boussignac Cardio-vascular catheter for shooting a laser beam
US4905690A (en) * 1986-06-30 1990-03-06 Medical Laser Research Co., Ltd. Semiconductor laser treatment device
US4926227A (en) * 1986-08-01 1990-05-15 Nanometrics Inc. Sensor devices with internal packaged coolers
US4749913A (en) * 1987-04-17 1988-06-07 General Electric Company Operating circuit for a direct current discharge lamp
US4745909A (en) * 1987-05-15 1988-05-24 Pelton Robert J Cold massage tool and method of use thereof
US4860744A (en) * 1987-11-02 1989-08-29 Raj K. Anand Thermoelectrically controlled heat medical catheter
US4930504A (en) * 1987-11-13 1990-06-05 Diamantopoulos Costas A Device for biostimulation of tissue and method for treatment of tissue
US4860172A (en) * 1988-01-19 1989-08-22 Biotronics Associates, Inc. Lamp-based laser simulator
US4884560A (en) * 1988-07-11 1989-12-05 Kuracina Thomas C Thermal massage device
US4928038A (en) * 1988-09-26 1990-05-22 General Electric Company Power control circuit for discharge lamp and method of operating same
US4945239A (en) * 1989-03-29 1990-07-31 Center For Innovative Technology Early detection of breast cancer using transillumination
US5057104A (en) * 1989-05-30 1991-10-15 Cyrus Chess Method and apparatus for treating cutaneous vascular lesions
US5059192A (en) * 1990-04-24 1991-10-22 Nardo Zaias Method of hair depilation
US5071417A (en) * 1990-06-15 1991-12-10 Rare Earth Medical Lasers, Inc. Laser fusion of biological materials
US5065515A (en) * 1991-01-24 1991-11-19 Warner-Lambert Company Thermally assisted shaving system
US20020128695A1 (en) * 1999-07-07 2002-09-12 Yoram Harth Apparatus and method for high energy photodynamic therapy of acne vulgaris and seborrhea
US20020173780A1 (en) * 2001-03-02 2002-11-21 Altshuler Gregory B. Apparatus and method for photocosmetic and photodermatological treatment
US7540869B2 (en) * 2001-12-27 2009-06-02 Palomar Medical Technologies, Inc. Method and apparatus for improved vascular related treatment

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070073308A1 (en) * 2000-12-28 2007-03-29 Palomar Medical Technologies, Inc. Method and apparatus for EMR treatment
US8915948B2 (en) 2002-06-19 2014-12-23 Palomar Medical Technologies, Llc Method and apparatus for photothermal treatment of tissue at depth
US10556123B2 (en) 2002-06-19 2020-02-11 Palomar Medical Technologies, Llc Method and apparatus for treatment of cutaneous and subcutaneous conditions
US10500413B2 (en) 2002-06-19 2019-12-10 Palomar Medical Technologies, Llc Method and apparatus for treatment of cutaneous and subcutaneous conditions
US10434324B2 (en) 2005-04-22 2019-10-08 Cynosure, Llc Methods and systems for laser treatment using non-uniform output beam
US10966785B2 (en) 2006-08-02 2021-04-06 Cynosure, Llc Picosecond laser apparatus and methods for its operation and use
US10849687B2 (en) 2006-08-02 2020-12-01 Cynosure, Llc Picosecond laser apparatus and methods for its operation and use
US11712299B2 (en) 2006-08-02 2023-08-01 Cynosure, LLC. Picosecond laser apparatus and methods for its operation and use
US9028536B2 (en) 2006-08-02 2015-05-12 Cynosure, Inc. Picosecond laser apparatus and methods for its operation and use
US9780518B2 (en) 2012-04-18 2017-10-03 Cynosure, Inc. Picosecond laser apparatus and methods for treating target tissues with same
US10581217B2 (en) 2012-04-18 2020-03-03 Cynosure, Llc Picosecond laser apparatus and methods for treating target tissues with same
US11664637B2 (en) 2012-04-18 2023-05-30 Cynosure, Llc Picosecond laser apparatus and methods for treating target tissues with same
US10305244B2 (en) 2012-04-18 2019-05-28 Cynosure, Llc Picosecond laser apparatus and methods for treating target tissues with same
US11095087B2 (en) 2012-04-18 2021-08-17 Cynosure, Llc Picosecond laser apparatus and methods for treating target tissues with same
US10245107B2 (en) 2013-03-15 2019-04-02 Cynosure, Inc. Picosecond optical radiation systems and methods of use
US10765478B2 (en) 2013-03-15 2020-09-08 Cynosurce, Llc Picosecond optical radiation systems and methods of use
US10285757B2 (en) 2013-03-15 2019-05-14 Cynosure, Llc Picosecond optical radiation systems and methods of use
US11446086B2 (en) 2013-03-15 2022-09-20 Cynosure, Llc Picosecond optical radiation systems and methods of use
US20160114183A1 (en) * 2014-10-24 2016-04-28 The Board Of Trustees Of The University Of Illinois Use of lasers for treating and reversing fibrosis
US11000694B2 (en) * 2014-10-24 2021-05-11 The Board Of Trustees Of The University Of Illinois Use of lasers for treating and reversing fibrosis
US20160143692A1 (en) * 2014-11-22 2016-05-26 Candela Corporation Laser System For Skin Treatment
US11418000B2 (en) 2018-02-26 2022-08-16 Cynosure, Llc Q-switched cavity dumped sub-nanosecond laser
US11791603B2 (en) 2018-02-26 2023-10-17 Cynosure, LLC. Q-switched cavity dumped sub-nanosecond laser

Also Published As

Publication number Publication date
AU2002367397A1 (en) 2003-07-24
WO2003057059A1 (en) 2003-07-17
US20040010298A1 (en) 2004-01-15
US7540869B2 (en) 2009-06-02

Similar Documents

Publication Publication Date Title
US7540869B2 (en) Method and apparatus for improved vascular related treatment
Patil Overview of lasers
Alster et al. Lasers in dermatology: an overview of types and indications
Kuperman-Beade et al. Laser removal of tattoos
Ross et al. Intense pulsed light and laser treatment of facial telangiectasias and dyspigmentation: some theoretical and practical comparisons
Clement et al. Optimising the design of a broad‐band light source for the treatment of skin
US20020173780A1 (en) Apparatus and method for photocosmetic and photodermatological treatment
Grunewald et al. Update dermatologic laser therapy
US20060084953A1 (en) Multibeam laser for skin treatment
Bahmer et al. Recommendation for laser and intense pulsed light (IPL) therapy in dermatology
Bjerring Photorejuvenation–an overview
Alster Laser treatment of hypertrophic scars
US20070088408A1 (en) Methods of reducing dermal melanocytes
Trelles et al. Nd: YAG laser combined with IPL treatment improves clinical results in non‐ablative photorejuvenation
Yang et al. Multi-wavelength laser treatments of spider nevi
Geronemus Laser surgery 1995
Rossi et al. Laser therapy in Latino skin
Trelles et al. Monoline argon laser (514 nm) treatment of benign pigmented lesions with long pulse lengths
Khamees et al. The use of lasers (ablative laser, non-ablative laser, fractional laser, photobiomodulation (PBM)) in skin regeneration
Harsh et al. Facial laser surgery
Ullmann et al. The aesthetic applications of intense pulsed light using the Lumenis M-22 device
Gerber Quality-Switched Ruby Laser
Lee et al. Intense Pulse Light (IPL) and Extended Theory of Selective Photothermolysis
Nelson Laser in Plastic Surgery and Dermatology
Wheeland Advances in laser surgery

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: PALOMAR MEDICAL TECHNOLOGIES, LLC, MASSACHUSETTS

Free format text: MERGER;ASSIGNOR:PALOMAR MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:031936/0704

Effective date: 20130624